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ABBREVIATIONS 
MT, microtubule; ATI, arylthioindole; CSA4, combretastatin A-4; VBL, vinblastine; PTX, 
paclitaxel; VRB, vinorelbine; SAR, structure-activity relationship; Pmax, maximum pressure; BOP 
reagent, benzotriazol-1-yloxytris(dimethylamino)-phosphonium hexafluorophosphate; Pd2(dba)3, 
tris(dibenzylideneacetone)dipalladium(0); P(Cy), tricyclohexylphosphine; Pd(dppf)Cl2·CH2Cl2, 1,1′-
bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane; PdCl2(PPh3)2, 
bis(triphenylphosphine) palladium(II) dichloride; Pd(OAc)2, palladium(II) acetate; Pd(PPh3)4, 
tetrakis(triphenylphosphine)palladium(0); SPhos, 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl; 
MI, mitotic index; DAPI, 4',6-diamidino-2-phenylindole; Pgp, P-glycoprotein; FBS, fetal bovine 
serum; CCCP, carbonyl cyanide m-chlorophenylhydrazone; DCFH2-DA, 6-carboxy-2',7'-
dichlorodihydrofluorescein diacetate; ROS, reactive oxygen species; JC-1, 5,5’,6,6’-tetrachloro-
1,1’3,3’-tetraethylbenzimidazoyl carbocyanine iodide; FDA, green-fluorescent form of DCFH2-DA; 
VDA, vascular disrupting agent. 
 
 ABSTRACT 
New arylthioindole derivatives having different cyclic substituents at position 2 of the indole were 
synthesized as anticancer agents. Several compounds inhibited tubulin polymerization at 
submicromolar concentration and inhibited cell growth at low nanomolar concentrations. Compound 18 
and 57 were superior to the previously synthesized 5. Compound 18 was exceptionally potent as an 
inhibitor of cell growth: it showed an IC50 = 1.0 nM in MCF-7 cells, and it was uniformly active in the 
whole panel of cancer cells and superior to colchicine and combretastatin A-4. Compounds 18, 20, 55 
and 57 were notably more potent than vinorelbine, vinblastine and paclitaxel in the NCI/ADR-RES and 
Messa/Dx5 cell lines, which overexpress P-glycoprotein. Compounds 18 and 57 showed initial vascular 
disrupting effects in a tumor model of liver rhabdomyosarcomas at 15 mg/kg intravenous dosage. 
Derivative 18 showed water solubility and higher metabolic stability than 5 in human liver 
microsomes. 
 
 
INTRODUCTION 
Microtubules (MTs) are involved in many essential cellular functions, e.g. the maintenance of cell 
shape, cell motility, intracellular transport and cell division. Cellular MTs undergo continuous 
polymerization and depolymerization transitions. Interference with this dynamic equilibrium, by either 
inhibiting tubulin polymerization or blocking MT disassembly, prevents proper MT function and 
ultimately leads to cell death. Because of their crucial role in the formation of the mitotic spindle 
during cell division, MTs are a highly attractive target for the development of new effective anticancer 
agents.1-5 
Natural products such as colchicine (1),6,7 combretastatin A-4 (CSA4, 2)8 (Chart 1) and the 
Catharanthus alkaloids vincristine and vinblastine (VBL) inhibit MT assembly by preventing tubulin 
polymerization. On the other hand, taxoids and epothilones target a lumenal site on the -subunit.9,10 
These drugs enter the lumen through a binding site11 located at a pore on the MT surface formed by 
different tubulin heterodimers. At high concentrations, paclitaxel (PTX) stimulates MT polymerization 
and stabilizes microtubules, whereas at lower concentrations it inhibits MT dynamics with little effect 
on the proportion of tubulin in polymer.12 Despite substantial interest in the development of new MT-
targeting drugs,13 several problems related to drug resistance and secondary toxicity remain 
unresolved. Therefore, new and improved tubulin inhibitors are needed.14 
Arylthioindoles (ATIs) are a class of potent inhibitors of tubulin polymerization and cancer cell 
growth developed by our research group.15-19 The ATIs inhibit tubulin polymerization by binding to 
the colchicine site, inhibiting the binding of [3H]colchicine to tubulin.15
 
In our previous work,19 we obtained new ATIs by replacing the 2-alkoxycarbonyl group with a 
bioisosteric 5-membered heterocycle nucleus. The new ATIs (i.e., 3-6) inhibited tubulin 
polymerization, inhibited the growth of a panel of human transformed cell lines, and showed higher 
metabolic stability than the reference ester (see example in Chart 1).  
Chart 1. General Structure of ATI Derivatives 7-78 and Reference Compounds 1-6. 
 
 
 
R1 = azolyl, azinyl, phenyl or substituted phenyl, naphthyl, biphenyl, benzofused heterocyclyl, alkyl, cycloalkyl; R2 = H; X 
= S, C=O, CHOH or CH2 (Tables 1 and 2). 
 
 
 
These new ATIs showed significant therapeutic potential, as they induced mitotic arrest and 
apoptosis similarly to 2 and VBL and triggered caspase-3 expression in a significant fraction of cells in 
both p53-positive and p53-negative cell lines.20 Importantly, some ATIs were more effective than 
VRB, VBL and PTX as growth inhibitors of the P-glycoprotein-overexpressing cell line NCI/ADR-
RES. These compounds had a pharmacokinetic profile in the mouse characterized by low systemic 
clearance and excellent oral bioavailability. On the basis of these observations, the current study was 
designed to explore further chemical modifications of the 5-membered heterocycle nucleus at position 
2 of the indole. We describe the synthesis and biological evaluation of new ATI derivatives 7-78 with 
different biososteric rings at position 2, with a sulfur bridge between the ring systems, or with other 
bioisosteric groups at position 3 of the indole (Table 1).  
CHEMISTRY 
ATI derivatives 17, 18, 20, 27, 33, 34, 38, 39, 41, 43, 45, 46, 47, 53, 55, 57, 73, 75 and 77 were 
synthesized by microwave reaction of an appropriate indole 79-87 with bis(3,4,5-
trimethoxyphenyl)disulfide in the presence of sodium hydride in a closed vessel at 110 °C while 
irradiating at 150 W for 2 min (Scheme 1). Compounds 14, 16, 37, 48, 59, 62, 72 were obtained by 
heating at 60 °C in DMF the corresponding indole 98-104 with bis(3,4,5-trimethoxyphenyl)disulfide in 
the presence of sodium hydride. Acids 105 and 106 were similarly transformed into the corresponding 
sulfides 107 and 108, respectively. Acid 107 was then converted into ATI 28 by treatment with 
bromoethylamine hydrobromide in the presence of benzotriazol-1-
yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP reagent) and triethylamine. Iodo 
derivative 108 was transformed into ATI 66 or 67 by heating at 110 °C with an appropriate boronic 
acid pinacol ester in the presence of 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) 
complex with dichloromethane (Pd(dppf)Cl2·CH2Cl2) and potassium phosphate in anhydrous DMF. 
Organostannane reactions of 108 with 2-(triethylstannyl)-1H-indole-1-carboxylic acid in the presence 
of bis(triphenylphosphine)palladium(II) dichloride (PdCl2(PPh3)2) in boiling ethanol for 48 h or 2-
(tributylstannyl)oxazole, tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) and 
tricyclohexylphosphine P(Cy)3 in anhydrous DMF at 150 °C and 150 W afforded 68 or 31, 
respectively. The synthesis of 69 was performed by heating 108 at 100 °C in aqueous 1,4-dioxane in 
the presence of 2-benzofuranyl boronic acid, palladium(II) acetate and potassium phosphate. ATI 70 
was synthesized by reaction of 108 with benzo[b]thien-2-yl boronic acid in the presence of 
tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4) and potassium carbonate in tetrahydrofuran at 60 
°C. Compound 71 was obtained from 108 and benzo[b]thien-3-yl boronic acid in the presence of 
Pd2(dba)3, 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (SPhos) and potassium phosphate in n-
butanol at 100 °C. 
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aReagents and reaction conditions. (a): (i) indole 79-97 (R1 = imidazol-2-yl (79), imidazol-1-yl (80),21 1,2,4-triazol-1-yl 
(81), thiazol-2-yl (82), 4,5-dihydro-1H-imidazol-2-yl (83), phenyl (84), 4-chlorophenyl (85), 2-fluorophenyl (86), 3-
fluorophenyl (87), 4-fluorophenyl (88), 2-methoxyphenyl (89), 3-methoxyphenyl (90), 4-methoxyphenyl (91), pyridin-2-yl 
(92), pyridin-3-yl (93), pyridin-4-yl (94), cyclobutyl (95), cyclopentyl (96), cyclohexyl (97)), NaH, anhydrous DMF, 25 °C, 
10 min; (ii), closed vessel, 110 °C, 150 W, 2 min, yield 3-77%; (b): (i) indole 98-104 (R1 = pyrazol-4-yl (98), pyrazol-3-yl 
(99),22 4-tolyl (100), 3-isopropoxy-4-methoxyphenyl (101), naphth-1-yl (102), naphth-2-yl (103), 1,1'-biphenyl-4-yl (104), 
COOH (105), I (106)23), NaH, anhydrous DMF, 0 °C, 15 min, Ar stream; (ii), 60 °C, 12 h, Ar stream, 35-72%; (c): Et3N, 
BOP reagent, anhydrous DMF, 25 °C, 2 h, 30%; (d): 6-quinolineboronic acid pinacol ester (for 66) or 1-Boc-indole-5-
boronic acid pinacol ester (for 67), Pd(dppf)Cl2·CH2Cl2, K3PO4, anhydrous DMF, Ar stream, 110 °C, 12 h, yield 26-70%; 
(e): 2-(triethylstannyl)-1H-indole-1-carboxylic acid24 PdCl2(PPh3)2, ethanol, reflux, 78 °C, 48 h, Ar stream, yield 20%; (f) 
2-(tributylstannyl)oxazole, Pd2(dba)3, P(Cy)3, anhydrous DMF, closed vessel, 150 °C, 150 W, 10 min, yield 35%; (g), 2-
benzofuranyl boronic acid, Pd(OCOMe)2, K3PO4, 1,4-dioxane/H2O, 100 °C, 24 h, Ar stream, yield 88%; (h) benzo[b]thien-
2-ylboronic acid, Pd(PPh3)4, Na2CO3, THF, 60 °C, 24 h, Ar stream, yield 10%; (i), benzo[b]thien-3-ylboronic acid, 
Pd2(dba)3, SPhos, K3PO4, n-BuOH, Ar stream, 100 °C, 12 h, yield 36%. 
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aReagents and reaction conditions. (a): (i) indole 80, 92-94, 98, 102, 109 (R1 = imidazol-1-yl (80),21 pyridin-2-yl (92), 
pyridin-3-yl (93), pyridin-4-yl (94), pyrazol-4-yl (98), naphth-1-yl (102), pyrrol-2-yl (109),25 MeMgBr, anhydrous ZnCl2, 
anhydrous CH2Cl2, 25 °C, 1 h, Ar stream; (ii) 3,4,5-trimethoxybenzoyl chloride, 25 °C, 1 h, Ar stream; (iii) SnCl4, 25 °C, 12 
h, Ar stream, yield 3-67%; (b): indole 86-88, 91, 94-96, 103, 110-114 (R1 = phenyl (84), 2-fluorophenyl (86), 3-
fluorophenyl (87), 4-fluorophenyl (88), 4-methoxyphenyl (91), cyclobutyl (94), cyclopentyl (95), cyclohexyl (96), naphth-
2-yl (103), 1-(phenylsulfonyl)-1H-pyrrol-3-yl (110),19 furan-2-yl (111),19 furan-3-yl (112),19 thiophen-3-yl (113),19 oxazol-
2-yl (114)), 3,4,5-trimethoxybenzoyl chloride, anhydrous AlCl3, 1,2-dichloroethane, closed vessel, 110 °C, 150 W, 2 min, 
yield 5-95%; (c): BH3/THF, MeCN/MeOH, 50 °C, 1 h, Ar stream, yield 4-99%; (d) 2 M NaOH, MeOH, reflux, 3 h, yield 
20-98%; (e) NaBH4, THF/H2O, 80 °C, 2 h, yield 44-97%. 
 
 
Ketones 7, 15, 19, 54, 56, 58 and 60 were prepared by reaction of indoles 80, 92-94, 98, 102 and 
109 with methylmagnesium bromide in the presence of anhydrous zinc chloride at 25 °C and 
subsequent treatment with 3,4,5-trimethoxybenzoyl chloride and tin(IV) chloride (Scheme 2). Ketones 
9, 21, 23, 25, 32, 35, 40, 42, 44, 51, 63, 74, 76 and 78 were obtained by reaction of the appropriate 
indole 86-88, 91, 94-96, 103 and 110-114 with 3,4,5-trimethoxybenzoyl chloride in the presence of 
anhydrous aluminum chloride. Reduction of ketones 9, 21, 23, 25, 35, 51, 60 and 63 with borane-
tetrahydrofuran complex solution in acetonitrile/methanol at 50 °C for 1 h afforded the corresponding 
methylene compounds 12, 22, 24, 26, 36, 52, 61 and 65. Sodium hydroxide hydrolysis of 9, 11 
(obtained by sodium borohydride reduction of 9) or 12 in boiling methanol provided ketone 8, 10 or 23, 
respectively. 
2-(1H-Pyrazol-4-yl)-1H-indole (98) was synthesized by microwave reaction of 106 with 1-Boc-
pyrazole-4-boronic acid pinacol ester in the presence of PdCl2(PPh3)2, 1 M Na2CO3 and DMF in a 
closed vessel at 160 °C while irradiating at 250 W for 10 min (Scheme 3). Solvent-free reaction at 150 
°C of 106 with 1,2,4-triazole furnished 2-(1H-1,2,4-triazol-1-yl)-1H-indole (81). 2-(1H-Indol-2-
yl)oxazole (114) was obtained as 31 by microwave reaction of 106 with 2-(tributylstannyl)oxazole in 
the presence of Pd2(dba)3 and P(Cy)3 in anhydrous DMF at 150 °C and 150 W. 2-(4,5-Dihydro-1H-
imidazol-2-yl)-1H-indole (83) was prepared by treatment of 1H-indole-2-carbaldehyde (115)26 with 
ethylene diamine and subsequent iodine oxidation in the presence of potassium carbonate. The 1-
phenylethanones were converted into 2-bromo-1-phenylethanones 116-121 with bromine in 
dichloromethane and then transformed into the corresponding 2-phenylindoles 86-90, 101 and 102 by 
heating at 170 °C with aniline in N,N-dimethylaniline. Microwave reaction of 2-bromo-1-(thiazol-2-
yl)ethanone27 (116) with aniline in a closed vessel at 150 °C and 100 W for 1 min afforded 88. o-
toluidides 123-127 were transformed into the corresponding indoles 100, 104 and 95-97 with butyl 
lithium in anhydrous tetrahydrofuran while the reaction was warmed from -40 °C to 25 °C. 
Phenylhydrazono derivatives 128-133 underwent Fischer cyclization in polyphosphoric acid at 120 °C 
to give indoles 85, 91-94 and 103. 
 
 
Scheme 3.a  
 
 
 
R2 = 2-F-Ph (86), 3-F-Ph (87), 4-F-Ph (88), 2-MeO-Ph (89), 3-MeO-Ph (90), 3-i-PrO-4-MeO-Ph (101), 1-naphthyl (102); R3 = 
cyclobutyl (95), cyclopentyl (96), cyclohexyl (97), 4-Me-Ph (100), 1,1'-biphenyl-4-yl (104); R4 = 4-Cl-Ph (85), 4-MeO-Ph (91), 
pyridin-2-yl (92), pyridin-3-yl (93) pyridin-4-yl (94), 2-naphthyl (103). 
 
aReagents and reaction conditions. (a): PdCl2(PPh3)2, 1 M Na2CO3, DMF, closed vessel, 160 °C, 250 W, 10 min, yield 26%; 
(b) 150 °C, 2 h, yield 42%; (c) Pd2(dba)3, P(Cy)3, anhydrous DMF, closed vessel, 150 °C, 150 W, 10 min, yield 26%; (d) (i) 
tert-BuOH, Ar stream, 30 min; (ii) I2, K2CO3, 70 °C, 3 h, yield 43%; (e) (diacetoxyiodo)benzene, K2CO3, DMSO, 25 °C, 12 
h; (f) anhydrous DMF, closed vessel, 150 °C, 100 W, 1 min, PowerMAX, yield 52%; (g) Br2, anhydrous CH2Cl2, 25 °C, 2 
h, yield 21-90%; (h) R2 = 2-F (116), 3-F (117), 4-F (118), 2-MeO (119),28 3-MeO (120),28 3-i-PrO-4-MeO (121), 1-
naphthyl (122), N,N-dimethylaniline, 170 °C, 15 min, yield 12-42%;; (i) R3 = 4-tolyl (123), 1,1'-biphenyl-4-yl (124), 
cyclobutyl (125), cyclopentyl (126), cyclohexyl (127), anhydrous THF, 25 °C, 12 h, yield 40-90%; (j) (i) n-BuLi, anhydrous 
THF, -40 °C, 1 h, Ar stream; (ii) 0 °C, 1 h; (iii) 25 °C, 12 h, yield 22-59%; (k) R4 = 4-Cl-Ph (128), 4-MeO-Ph (129), 
pyridin-2-yl (130),29 pyridin-3-yl (131),29 pyridin-4-yl (132),29 2-naphthyl (133),29 CH3COONa, EtOH, open vessel, 250 W, 
air-cooling, 80 °C, 5 min, yield 92-95%; (l) polyphosphoric acid, 120 °C, 1 h, yield 37-80%. 
Table 1. Inhibition of Tubulin Polymerization, Growth of MCF-7 Human Breast Carcinoma Cells and 
Colchicine Binding by Compounds 7-78. 
 
N
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Compd R1 X 
Tubulin Assemblya 
IC50 ± SD 
(M) 
MCF-7b 
IC50 ± SD 
(nM) 
Colchicine 
Bindingc 
(% ± SD) 
7 
 
C=O 1.4 ± 0.2 10 ± 0 79 ± 3 
8 
 
C=O 1.8 ± 0.2 35 ± 7 71 ± 0.7 
9 
 
C=O 29 ± 1 ndd ndd 
10 
 
CHOH 1.8 ± 0.1 30 ± 0 70 ± 6 
11 
 
CHOH 9.0 ± 1 nd nd 
12 
 
CH2 >40 nd nd 
13 
 
CH2 3.0 ± 0.2 600 ± 0 56 ± 7 
14 
 
S 0.92 ± 0.2 35 ± 20 81 ± 1 
15 
 
C=O 1.7 ± 0.04 25 ± 7 68 ± 1 
16 N NH
 
S 1.2 ± 0.1 50 ± 10 78 ± 0.5 
17 
 
S 4.6 ± 0.4 270 ± 60 29 ± 3 
18 
 
S 1.3 ± 0.06 1.0 ± 0.5 92 ± 0.8 
19 
 
C=O 3.5 ± 0.2 120 ± 0 42 ± 2 
20 
 
S 1.2 ± 0.1 11 ± 4 83 ± 1 
21 
 
C=O 1.9 ± 0.2 55 ± 7 78 ± 0.3 
22 
 
CH2 6.8 ± 1 nd nd 
23 
 
C=O 1.1 ± 0.007 40 ± 20 77 ± 0.8 
24 
 
CH2 6.5 ± 0.08 nd nd 
25 
 
C=O 2.1 ± 0.08 40 ± 0 61 ± 3 
26 
 
CH2 2.7 ± 0.08 340 ± 200 52 ± 4 
27 
 
S 0.96 ± 0.1 80 ± 20 72 ± 6 
28 
 
S 3.3 ± 0.6 160 ± 50 37 ± 0.8 
29 
 
C=O 14 ± 0.8 nd nd 
30 
 
CH2 9.4 ± 0.01 nd nd 
31 
 
S 4.5 ± 0.2 270 ± 60 51 ± 2 
32 
 
C=O 3.4 ± 0.2 80 ± 0 44 ± 5 
33 
 
S >40 nd nd 
34 
 
S 3.3 ± 0.1 52 ± 7 nd 
35 
 
C=O 5.7 ± 0.06 87 ± 20 nd 
36 
 
CH2 3.7 ± 0.3 170 ± 60 50 ± 3 
37 
 
S 0.94 ± 0.08 70 ± 40 61 ± 3 
38 
 
S 1.8 ± 0.2 190 ± 20 50 ± 3 
39 
F
 
S 1.7 ± 0.2 50 ± 0 74 ± 2 
40 
F
 
C=O 2.1 ± 0.1 60 ± 10 55 ± 2 
41 
F
 
S 1.7 ± 0.04 63 ± 4 75 ± 0.6 
42 
F
 
C=O 7.6 ± 0.4 nd nd 
43 F
 
S 1.8 ± 0.2 63 ± 4 74 ± 0.06 
44 F
 
C=O 9.4 ± 0.2 nd nd 
45 
 
S 3.3 ± 0.06 530 ± 60 25 ± 8 
46 
 
S 3.6 ± 0.1 73 ± 20 32 ± 20 
47 
 
S 0.94 ± 0.08 56 ± 7 47 ± 1 
48 
 
S >40 nd nd 
49 
 
S 1.1 ± 0.08 140 ± 20 68 ± 3 
50 
 
S >40 nd nd 
51 
 
C=O 4.1 ± 0.6 200 ± 40 24 ± 5 
52 
 
CH2 >40 nd nd 
53 
 
S 1.5 ± 0.2 180 ± 80 48 ± 6 
54 
 
C=O > 20 330 ± 100 nd 
55 
 
S 1.3 ± 0.07 12 ± 7 88 ± 0.1 
56 
 
C=O 6.3 ± 0.7 200 ± 100 nd 
57 
 
S 0.95 ±  0.1 16 ± 10 91 ± 2 
58 
 
C=O 6.0 ± 0.6 170 ± 60 nd 
59 
 
S >40 nd nd 
60 
 
C=O >40 nd nd 
61 
 
CH2 >40 nd nd 
62 
 
S 1.0 ± 0.06 530 ± 50 51 ± 6 
63 
 
C=O >40 nd nd 
64 
 
CHOH >40 nd nd 
65 
 
CH2 >40 nd nd 
66 
 
S 4.0 ±  0.1 900 ± 0 29 ± 6 
67 
 
S 3.1 ±  0.3 450 ± 0 46 ± 7 
68 N
H
 
S 1.8 ±  0.1 150 ± 70 57 ± 3 
69 
O
 
S 1.5 ±  0.1 110 ± 7 59 ± 0.7 
70 
S
 
S 1.7 ± 0.1 580 ± 50 52 ± 5 
71 
S
 
S >40 nd nd 
72 
 
S >40 nd nd 
73 
 
S 2.0 ± 0.08 150 ± 50 43 ± 1 
74 
 
C=O 2.8 ± 0 .2 110 ± 20 42 ± 5 
75 
 
S 2.6 ± 0.08 200 ± 0 38 ± 5 
76 
 
C=O 4.0 ± 0.08 170 ± 50 33 ± 5 
77 
 
S >20 430 ± 200 nd 
78 
 
C=O >20 1500 ± 700 nd 
1       - - 3.2 ± 0.4 5 ± 1 - 
2       - - 1.0 ± 0.1 13 ± 3 98 ± 0.6 
3e 
 
S 1.1 ± 0.05 18 ± 6 90 ± 4 
4e 
 
S 1.2 ± 0.2 20 ± 0 85 ± 1 
5e 
 
S 0.74 ± 0.05 39 ± 10 86 ± 0.7 
6e 
 
C=O 1.0 ± 0.1 36 ± 6 75 ± 3 
aInhibition of tubulin polymerization. Tubulin was 10 M during polymerization. bInhibition of growth of MCF-
7 human breast carcinoma cells. cInhibition of [3H]colchicine binding, tubulin was at 1 M, both [3H]colchicine 
and inhibitor were at 5 M.  dCompounds that inhibited tubulin assembly with IC50’s ≤5 M were tested in the 
cellular and colchicine binding assays. eLit.19 Plots of inhibition of tubulin polymerization and MCF-7 cell 
growth by compounds 7-78 are shown in Supporting Information. 
 
 
 
 
RESULTS AND DISCUSSION 
Inhibition of Tubulin Polymerization. The effects of ATIs 7-78 on tubulin polymerization in vitro 
are shown in Table 1. On the basis of our previous results,18,19 we synthesized these compounds to 
obtain structure-activity relationship (SAR) information regarding position 2 of the indole moiety and 
the sulfur bridging group. Several new ATIs (7, 8, 10, 15, 16, 18, 20, 21, 23, 38, 39, 41, 43, 49, 53, 55, 
68-70 and 73) inhibited tubulin polymerization with IC50’s of 1.0-2.0 µM, and six compounds (14, 27, 
37, 47, 57 and 62) yielded IC50’s ≤1.0 M, as compared with 1.0 µM obtained for CSA4 (2) and 3.2 
µM for colchicine (1). 
For SAR studies regarding the sulfur bridging group, we synthesized 3-aroylindoles and several 
corresponding alcohol and methylene derivatives as potential bioisosteres of previously reported 
ATIs.19 As tubulin polymerization inhibitors, ketones 7 and 8 were less potent than their sulfur 
counterparts 3 and 4, respectively, as well as less active than the similar compounds 5 and 6. Similar 
results were were also obtained with ketones 21, 23 and 25 in comparison with the corresponding 
arylthioindoles.19 Reduction of the ketone 8 to alcohol 10 resulted in an equipotent inhibitor of tubulin 
polymerization. Replacement of the sulfur bridging atom with a methylene group invariably caused a 
drop, sometimes dramatic, in inhibitory activity (cf. 4 with 13, 34 with 36, 28 with 30, 47 with 52, and 
62 with 65). 
Replacement of the pyrrol-3-yl group of 4 with a pyrazol-4-yl moiety provided ATI compound 14 
(IC50 = 0.92 M), which was more potent than the parent compound as an inhibitor of tubulin 
polymerization. This observation prompted the synthesis of new ATIs bearing a pyrazol-3-yl (16), 
imidazol-2-yl (17), imidazol-1-yl (18), 1,2,4-triazol-1-yl (20), thiazol-2-yl (27) or oxazol-2-yl (31) 
moiety at position 2 of the indole. With the exception of 17 and 31, these compounds potently inhibited 
tubulin polymerization with IC50’s ranging from 0.96 M (27) to 1.3 M (18). Again, the ketones were 
less potent than the parent sulfur compounds (compare 14 with 15, and 18 with 19). 
Introduction of a methyl, methoxy, chlorine or fluorine moiey at the para or meta position of a 
phenyl ring at indole position 2 also provided potent tubulin polymerization inhibitors (i.e. 37, 38, 41, 
43 and 47), as compared with the unsubstituted 34. Interestingly, ATI 49, bearing the 3-hydroxy-4-
methoxyphenyl substitution pattern (the same as 2) at indole position 2, inhibited tubulin assembly with 
an IC50 = 1.1 M, as compared with 1.0 µM for 2. Introduction of a pyridin-2-yl (53, IC50 = 1.5 µM), 
pyridin-3-yl (55, IC50 = 1.3 µM) or pyridin-4-yl (57, IC50 = 0.95 M) group resulted in potent 
inhibitors of tubulin assembly. The 2-naphthyl derivative 62 inhibited potently the tubulin 
polymerization (IC50 = 1.0 M), but the 1-naphthyl derivative 59 was inactive. Compounds 68-70, 
bearing a benzofused heterocycl-2-yl substituent at position 2 of the indole, inhibited tubulin assembly 
with IC50’s in the range of 1.5-1.8 µM. 
Molecular modeling studies were consistent with the conclusion that the binding modes of these 
new ATIs in the colchicine site on tubulin were similar to those of previously reported ATIs19 
(Supporting Information). 
The new ATIs were also examined for potential inhibition of the binding of [3H]colchicine to 
tubulin (Table 1). Compounds 7, 8, 10, 14, 16, 18, 20, 21, 23, 27, 39, 41, 43, 55 and 57 inhibited the 
binding reaction by at least 70%. Among them, 18 (92%), 55 (88%) and 57 (91%) were the strongest 
inhibitors of this binding reaction, as compared with 2 (98% inhibition). 
Cell Growth Inhibition. ATIs 7, 8, 10, 14-16, 18, 20, 21, 23, 25, 34, 39, 40, 47, 55 and 57 inhibited 
the growth of human MCF-7 non-metastatic breast cancer epithelial cells with IC50’s ≤60 nM (Table 1). 
Five compounds (7, 18, 20, 55 and 57) had IC50’s ≤16 nM, with 18 (IC50 = 1.0 nM) being the most 
potent. As an inhibitor of MCF-7 cell growth, 18  was 5- and 13-times more potent than 1 and 2, 
respectively. Moreover, this ATI was 18- to 39-times more effective than the reference ATI compounds 
3-6. 
Many of the new agents were potent inhibitors of tubulin polymerization; however, compounds 
bearing the heterocycle nucleus at the indole position 2 were more effective as inhibitors of the growth 
of MCF-7 cells. ATI 49, having the same substitution pattern as 2, was only a relatively weak inhibitor 
of MCF-7 cell growth (IC50 = 140 M). ATI derivatives 18 (IC50 = 1.0 nM) and 20 (IC50 = 11 nM), 
bearing an imidazol-1-yl or 1,2,4-triazol-1-yl nucleus, respectively, at indole position 2, were powerful 
inhibitors of the MCF-7 cell line. In contrast to 18, compounds 14 (IC50 = 35 nM), 16 (IC50 = 50 nM), 
17 (IC50 = 270 nM), 27 (IC50 = 80 nM) and 32 (IC50 = 270 nM), each having two heteroatoms in the 2-
heterocyclyl moiety, were less active inhibitors of the growth of this cell line.  
Compounds 7, 8, 10, 14, 15, 18, 20, 23, 25, 34, 47, 55 and 57 were evaluated for growth inhibition 
of  HeLa, HT29 (human colon adenocarcinoma), A549 (human lung carcinoma), HCT 116 and HCT 15 
(human colon carcinoma cell lines) in comparison with 1, 2, vinblastine (VBL) and paclitaxel (PTX) 
(Table 2). In terms of average IC50 for the five cell lines, the control compounds ranged from 17 to 40 
nM (ignoring the high value obtained with 2 in the A549 cells). The average value for 18, 21 nM, was 
in the same range, and six other compounds (7, 8, 14, 20, 55 and 57) had average IC50’s less than 100 
nM.  All these compounds had IC50’s of 35 nM or less in the screening assay in the MCF7 cells. 
 
 Table 2. Growth Inhibition of the HeLa, HT29, A549, HCT 116 and HCT 15 Cell Lines by Compounds 7, 
8, 10, 14, 15, 18, 20, 23, 25, 34, 47, 55 and 57.a 
 IC50 ± SD (nM)  
Compd HeLa HT-29 A549 HCT 116 HCT 15 Averageb 
7 94 ± 4 182 ± 1 50 ± 6 89 ± 37 38 ± 22 91 
8 120 ± 10 80 ± 16 68 ± 4 62 ± 5 52 ± 2 76 
10 134 ± 60 88 ± 3 94 ± 4 177 ± 41 75 ± 14 114 
14 188 ± 20 94 ± 30 80 ± 6 67 ± 2 62 ± 0.4 98 
15 97 ± 3 282 ± 5 112 ± 20 154 ± 34 175 ± 2 164 
18 30 ± 7 30 ± 4 20 ± 7 16 ± 6 11 ± 3 21 
20 180 ± 15 90 ± 25 75 ± 5 68 ± 2 50 ± 0.9 93 
23 154 ± 80 184 ± 70 82 ± 30 90 ± 43 53 ± 4 113 
25 350 ± 9 282 ± 6 90 ± 5 533 ± 95 119 ± 18 275 
34 288 ± 80 105 ± 10 137 ± 3 186 ± 1 160 ± 24 175 
47 482 ± 60 188 ± 10 285 ± 2 593 ± 18 394 ± 91 388 
55 48 ± 4 45 ± 6 28 ± 1 183 ± 5 84 ± 20 78 
57 47 ± 1 78 ± 32 75 ± 2 59 ± 5 47 ± 13 61 
1 28 ± 9 18 ± 4 20 ± 8 20 ± 2 86 ± 10 34 
2 20 ± 5 130 ± 12 >10000 5 ± 0.4 3 ± 9 >2032 
VBL 10 ± 0.6 30 ± 0.8 20 ± 2 3 ± 2 24 ± 10 17 
PTX 5 ± 1 8 ± 1.5 7 ± 2 4 ± 0.4 90 ±17 23 
aInhibition of growth of the indicated cell lines. bAverage activity of each compound was established for 
comparative purpose. 
 
 
MDR Cell Lines. Compounds 18, 20, 55 and 57 were compared with vinorelbine (VRB), VBL, 
PTX 1 and 2 in the ovarian carcinoma cell lines OVCAR-8 and its cognate P-glycoprotein (Pgp) 
overexpressing  line NCI/ADR-RES and to the human uterine sarcoma cell line Messa and its cognate 
line MDR line Messa/Dx5 (Table 3). Except for 2, the standard agents were relatively inactive in both 
MDR lines.  The four ATIs 18, 20, 55 and 57 closely ressembled 2 in having full activity in both MDR 
lines.  
 
Table 3. Growth Inhibition of the OVCAR-8 and NCI/ADR-RES, and Messa and Messa/Dx Cell 
Lines by Compounds 18, 20, 55 and 57 and Reference Compounds VRB, VBL, PTX, 1 and 2.a 
 IC50 ± SD (nM) 
Compd OVCAR-8 NCI/ADR-RES Messab Messa/Dx5b 
18 16 ± 6 20 ± 10 7 ± 0.3 13 ± 3 
20 28 ± 10 15 ± 7 45 ± 4 39 ± 6 
55 17 ± 6 23 ± 10 60 ± 7 71 ± 2 
57 7.0 ± 3 14 ± 7 49 ± 2 53 ± 14 
1 ndc nd 11 ± 6 329 ± 166 
2 1.3 ± 0.6 1.3 ± 0.6 2.7 ± 2 2.6 ± 1 
VRB 300 ± 0 5000 ± 1000 nd nd 
VBL 15 ± 7 200 ± 0 3 ± 2 144 ± 61 
PTX 5.0 ± 2 3300 ± 1000 4 ± 1 1764 ± 477 
aInhibition of growth of the indicated cell lines. bGrowth inhibition data of compounds 7, 8, 10, 
14, 15, 23, 25, 34 and 47 are shown in Supporting Information cNo data. 
 
 
Effects on cell cycle progression. The most potent compound 18, as well as 57, were tested in 
dose-response experiments in comparison with 2 and VBL for effects on cell cycle distribution. HeLa 
cell cultures were treated with increasing concentrations of each compound, and 0.1% DMSO, the 
compound solvent, was used as a control. Representative images (DNA distribution by flow cytometry 
and wide-field microscopic images) of unfixed cultures taken after 24 h of treatment are shown in 
Figure 1A. Compound 57 at 100 nM induced a significant increase in the proportion of cells in the 
G2/M phase and, presumably, in mitosis, based on their rounded morphology in the microscopic image. 
After treatment with 10 nM 18, a significant proportion of the cells had assumed the rounded shape 
characteristic of mitotic arrest, and at 50 nM virtually the entire population was rounded and arrested in 
G2/M, based on DNA content.  
 
 
 Figure 1. A. Analysis of HeLa cell cultures treated with 18 or 57 for 24 h by wide-field microscopy (left panels) and flow 
cytometry (right panels). The left panels in each group show representative fields from unfixed cultures (10 x objective): cells 
arrested in mitosis detach from the culture dish surface, leaving ample empty spaces, and are recognizable from their rounded-up 
refractive morphology. Cycling cultures are adherent with only rare rounded mitotic cells. Flow cytometry profiles of the cultures 
are shown on the right. The histrograms represent the ditribution of cells according to their DNA content calculated from the 
emitted PI fluorescence: fluorescence intensity values are plotted on the x axis and cell numbers are plotted on the y axis. The 2C 
peak (in grey) identifies G1 cells; the 4C peak (in blue) identifies G2/M cells. Cells with intermediate DNA content are in S phase. 
B. Mean frequency and SD of the frequency of cells with a 4C content (G2+M) under the indicated conditions. From 3 to 5 assays 
were carried out for every treatment, and data from 20.000 cells per assay were acquired.  
 To confirm the initial microscopic observations, treated cultures were incubated with propidium 
iodide and subjected to quantitative flow cytometric analysis of the cell cycle phase distribution. 
Typical cell cycle profiles of PI-stained cultures after 24 h of treatment are shown in Figure 1A, and 
average values calculated from 3 to 5 independent assays per compound are shown in Figure 1B. Both 
compounds 18 and 57 arrested cell cycle progression in the G2/M phases (4C DNA content) when used 
at 100 nM. Plotting the concentration of the tested ATI against the fraction of G2/M-arrested cells in 
treated cultures (Figure 1B) indicated that 18 was a potent inhibitor of cell cycle progression already at 
20 nM and induced a significant proportion of cells (46%) to arrest with a 4C DNA content, compared 
with 10.5% G2/M cells in control cultures. At higher concentrations, 18 progressively increased cell 
cycle arrest: at 50 nM, over 60 % cells in treated cultures were in G2/M phase (Figure 1B), similar to 
the values obtained with both VBL and CSA-4 (2). The accumulation of cells with a replicated genome 
demonstrated that 18, like the control drugs, prevented or impaired mitotic cell division. 
Compound 57 had somewhat milder effects on cell cycle progression (Figure 1B), as compared with 
18. Only about 48% of cells accumulated in the G2/M region with 57 at 50 nM; lower doses were 
virtually ineffective, with the proportion of G2/M cells essential identical to the values observed in 
untretated controls. Only when the concentration was raised to 100 nM was the majority (65%) of cells 
arrested in G2/M. 
 
 
 
 
  
 
Figure 2. A. Examples of immunofluorescenctly-stained cells. In all panels, the DNA is blue (stained with DAPI), -
tubulin is green and cyclin B1 is red, as indicated. Left: a G2 interphase cell identified by cyclin B1 expression; middle: a 
cell arrested in prometaphase with depolymerized microtubules (shown with and without merging with cyclin B1 staining); 
right: a multinucleated cell derived from mitotic slippage.  B. Distribution of cells in dose-response experiments with 18 and 
57. The histograms represent the mean frequency, and bars the SD, of interphases (I), mitoses (M) and multinculeated cells 
(MN) from three independent experiments.  
 
  
 Inhibition of microtubule assembly and induction of mitotic arrest. We analyzed cell 
cultures in dose-response experiments using fluorescence microscopy to gain information on the effects 
of 18 and 57 on cellular MTs. After treatment with increasing concentrations of 18 or 57 for 24 h, we 
stained treated cells for -tubulin, cyclin B1 and DAPI in order to discriminate between arrest in G2 
interphase (i.e., interphase cells expressing cyclin B1, Figure 2A, left panel) or in prometaphase (Figure 
2A, central panel). This is relevant because the molecular features of mitotic cell death are distinct, at 
least in part, from the classical apoptotic pathway induced in interphase.30 In some experiments, we 
also stained lamin B1 to visualize the integrity of the nuclear membrane and assess the stringency of 
mitotic arrest induced by ATI compounds. Indeed, cells with a defective mitotic apparatus do not 
necessarily arrest stably in prometaphase, but, depending on the extent of MT damage, they may finally 
exit mitosis (mitotic slippage) with abnormal chromosome segregation and/or failed cell division 
giving rise to multinucleated cells (Figure 2A, right panel). 
In dose-response experiments (Figure 2 B, bottom panel), we found that 57 at 10 and 20 nM did not 
affect mitotic progression (only 10% of all cells displayed mitotic properites, similar to the baseline 
frequency observed in control cells treated with DMSO). Although these concentrations induced many 
abnormal mitotic spindles (aberrantly shaped, multipolar and/or with sparse and rare MTs), cells were 
distributed in all mitotic stages, indicating that these abnormalities did not evoke a stringent spindle 
checkpoint, and cells progressed to divide. At 50 nM 57 induced some mitotic arrest: 47% of all cells 
were arrested in prometaphase with reduced numbers of MTs. This arrest was not absolutely stringent 
since 16% of cells in the culture were aberrant, multinucleated, post-mitotic species. 100 nM 57 
arrested almost 65% of cells stably in prometaphase with completely absent MTs and condensed 
chromosomes. Virtually no mitotic slippage was observed with this concentration. At 200 nM, the 
mitotic index decreased while the fraction of G2 interphases correspondingly increased, indicating such 
a strong effect on interphase MTs that cells were prevented from entering mitosis altogether.31 Indeed, 
a similar decrease in mitotic arrest, with a corresponding increase in G2 cells, is observed at high 
concentrations of 2 or VBL.    
Compound 18 showed the highest effectiveness, in terms of inducing mitotic arrest at 50 nM in 
HeLa cell cultures (Figure 2 B, top panel). At this concentration, 18 induced effective mitotic arrest in 
prometaphase with totally absent MTs and no significant mitotic slippage. ATI 18 blocked mitotic 
progression even at lower concentration (20 nM), yet the arrest was not fully sustained with this 
concentration, and some cells slipped through mitosis with a defective mitotic apparatus, generating 
multinucleated cells (18% of all cells). At 100 nM, 18 prevented M entry, suggesting an excessively 
strong effect on interphase MTs. Together, these data indicate that 18 is a strong inhibtior of MT 
polymerization and induced effective mitotic arrest at 50 nM, similar to 2 or VBL, whereas 57 induced 
a durable mitotic block when used at 100 nM. 
Induction of mitotic cell death. We examined whether the new ATIs 18 and 57, in addition to 
arresting mitosis, also triggered cell death. HeLa cell cultures were treated for 24 h as described above, 
and they were then incubated with annexin V in the absence of permeabilization in order to detect 
apoptotic cells with a damaged plasma membrane. They were then analyzed by flow cytometry (Figure 
3A). Significant cell death was detected in cultures exposed to 18 (50 and 100 nM) or 57 (100 nM) 
concentrations at which the cell populations displayed significant mitotic arrest (Figures 1 and 2). 
Biparametric analysis of annexin V reactivity versus genomic DNA content revealed that necrosis was 
negligible (Figure 3B). These data therefore show that both 18 and 57 induce mitotic cell death.  
 
 
 
 
  
Figure 3. A. Frequency of apoptotic cells in cultures treated with the indicated concentrations of compounds 
18 or 57. The histograms represent mean frequencies, and bars the SDs, of annexin V-reactive cells from 
three independent experiments. B. Biparametric analysis of cell death in dose-response experiments with 18. 
Early apoptotic, late apotptotic and necrotic cells are distinguished by their differential reactivity to Annexin 
V but not PI, or to both Annexin V and PI, or to PI but not Annexin V, respectively. Results from three 
independent experiments are shown for each concentration: no condition induced significant necrosis 
compared with the baseline level seen in DMSO-treated controls (data from 20.000 cells acquired per 
sample).  
 
 
 Loss of mitochondrial potential. We evaluated the loss of mitochondrial potential (ΔΨm), a 
hallmark for early induction of cellular apoptosis,32 to elucidate further whether compounds 18 and 57 
would induce apoptosis or necrotic death. The loss of ΔΨm was indicated by a decrease in red 
5,5’,6,6’-tetrachloro-1,1’3,3’-tetraethylbenzimidazoyl carbocyanine iodide (JC-1) aggregates, 
accompanied by a concomitant accumulation in green JC-1 monomers. The collapse in ΔΨm, as 
measured as reduction in the red/green fluorescence ratio, was assessed after cell treatment with 18 or 
57. As shown in Figure 4, after a 24 h treatment,  57 was able to induce a more significant reduction in 
ΔΨm than was 18. The standard compound carbonyl cyanide m-chlorophenylhydrazone (CCCP) 
caused about 50% potential dissipation at a concentration of 30 M. 
ROS generation. Mitochondria are an important intracellular source of reactive oxygen species 
(ROS).33 We measured the ability of compounds 18 and 57 to generate ROS in U87MG cells, using 
hydrogen peroxide specific probe 6-carboxy-2',7'-dichlorodihydrofluorescein diacetate (DCFH2-DA). 
The IC50 values of compounds 18 and 57 in U87MG (human glioblastoma) cell growth/survival 
after a 24 h treatment were determined. Compounds 18 and 57 showed dose-dependent inhibitory 
effects on cell survival, with compound 18 having an IC50 = 85 ± 8 nM and 57 an IC50 = 103 ± 9 nM. 
Compound-treated cells showed an increase in the percentage of cell death as compared with control 
cells, reaching statistical significance at a concentration of 100 nM. 
According to the observed loss of mitochondrial potential, both compounds 18 and 57 were able to 
increase ROS levels. The effect was not detectable immediately, but it reached statistical significance 
after a 1 h treatment (fluorescence intensity with respect to control: 18, 216%; 57, 254%, both greater 
than the value of 208% obtained with the usual standard, hydrogen peroxide (Figure 5). 
 Figure 4. Effects of a 24 h treatment with 100 nM 57 or 18 or 30 M CCCP on mitochondrial transmembrane potential as 
assessed by JC-1 staining. Graphs indicate the ΔΨ dissipation expressed as red/green (R/G) fluorescence ratio. Each value 
has been normalized versus the R/G ratio of the vehicle treated control to which an arbitrary value of 100% has been 
assigned. Data were the mean of two independent experiments performed in triplicate. (**= p<0.01 and ***p<0.001, 
Oneway Anova, Bonferroni’s corrected t-test for post-hoc pair-wise comparisons). 
 
 
 
Figure 5. Effects of treatment with 100 nM 57 or 18, and 400 mM H2O2 on ROS formation in U87MG cells after exposures 
of 1, 5, 15 and 60 min. The results are expressed as % of mean fluorescence intensity relative to the control and normalized 
for cell number. Data were the mean of two independent experiments performed in triplicate (*=p<0.05, **= p<0.01 and 
***p<0.001, Oneway Anova, Bonferroni’s corrected t-test for post-hoc pair-wise comparisons).
 Figure 6. Contrast enhanced MRI was used in rats with bifocal liver growths of rhabdomyosarcoma (smaller and larger 
arrows denote smaller and larger lesions, respectively). At baseline prior to treatment, the liver tumors appear as 
homogeneous hyperintense spheroidal nodules, suggesting their hypervascularity (A, A’). 1 h after intravenous injection of 
either 57 (B) or 18 (B’), the tumors were partially enhanced due to their early vascular disrupting effects, which appeared 
stronger with 18 (B’) than 57 (B). 24 h after treatment, the tumors treated with 57 were enhanced completely (C), 
suggesting only transient early vascular disruption effect and the absence of any consequent tumor necrosis. However, 
tumors treated with 18 showed rim (arrowheads) and partial central enhancement (C’), suggesting the presence of both 
tumor necrosis and viable residues.   
 
In vivo vascular disrupting effects. In preclinical development of new anticancer drugs such as 
vascular disrupting agents (VDAs), in vivo validation proved to be an indispensible step in the bench-
to-bedside chain, where animal models with tumor growth in visceral organs could better simulate 
clinical scenarios in comparison with the mostly applied subcutaneous implants.34 Magnetic resonance 
imaging (MRI) has greatly facilitated in vivo non-invasive assessment of tumoricidal effects on deeply 
seeded lesions in the animal models.35 Consequently, we were able to observe that, at the same 
intravenous dosage of 15 mg/kg, both compounds 18 and 57 exerted initial vascular disrupting effects 
in the applied tumor model of liver rhabdomyosarcomas. The observed tumor vascular shutdown effect 
seems stronger and lasts longer with 18 (B’ and C’) as compared to 57 (B and C). The reason for such 
different effects will be further elucidated (Figure 6).  
Table 4. Metabolic Stability with Human and Mouse Liver Microsomes a and Aqueous Solubility of 
Compounds 18, 20, 55 and 57. 
 % remaining at 30 min.b  
Compd Human Liver microsomes Mouse Liver microsomes Solubility (M)b,d 
18 48.6 ± 1.9 10.3 ± 0.4 64.5 ± 0.7 
20 12.0 ± 1.1 0.6 ± 0.1 4.0 ± 0.1 
55 19.3 ± 0.9 2.8 ± 0.3 20.5 ± 0.7 
57 17.7 ± 0.5 7.9 ± 0.2 5.0 ± 0.1 
7-Ethoxycoumarinc 6.6 ± 0.2 0.07 ± 0.02 - 
Propranololc 54.1 ± 0.4 20.6 ± 0.5 - 
aMetabolic stability: >50, good; 10-50, medium; <10, low. bResults are expressed as mean  SD,  n = 2. 
cThe standard compounds 7-ethoxycoumarin and propranolol showed metabolic stability in agreement 
with the literature and internal validation data.36 dpH 7.4, high throughput screening solubility assay. 
 
 
Metabolic stability. Compounds 18, 20, 55 and 57 were examined in a microsomal stability assay 
in comparison with 7-ethoxycoumarin and propranolol as control compounds, using both human and 
mouse liver microsomes, to estimate compound stability to phase I oxidative metabolism (Table 4). 
Compound 18 showed the highest metabolic stability with 48.6 % and 10.3 % remaining after 30 min 
in human and mouse liver microsomes, respectively. Compounds 20, 55 and 57 showed medium 
metabolic stability with human liver microsomes and low metabolic stability with mouse liver 
microsomes (relative stabilities are defined in Table 4 legend). 
Aqueous solubility. The solubility in aqueous pH 7.4 buffer of compounds 18, 20, 55 and 57 was 
measured in a high throughput screening solubility assay. The solubility of compound 18 was 64.5 M, 
while under the same conditions compounds 20 (4 M), 55 (20.5 M) and 57 (8 M) showed lower 
solubility (Table 4). The higher solubility of compound 18 could explain its greater activity as a cell 
growth inhibitor (see Table 1 and Table 2), although these compounds were comparable inhibitors of 
tubulin assembly in the biochemical assays. 
 
Table 5. Caco-2 Cell Permeability and CYP450 Isoform Inhibition of Compounds 18, 20, 55 and 57. 
 Papp  (nm/s).a  CYP450 Isoform (% inhibition at 1 M) 
Compd PA→B PB→A  CYP1A2 CYP2C19 CYP2C9 CYP2D6 CYP3A4 
18 55.3 ± 11.1 60.0 ± 5.6  22.9 ± 0.03 82.5 ± 0.01 95.9 ± 0.05 10.6 ± 0.16 94.5 ± 0.55 
20 132.5 ± 19.7 133.2 ± 4.2  <5 83.9 ± 0.21 93.1 ± 0.18 <5 51.4 ± 0.18 
55 53.1 ± 6.0 65.8 ± 2.5  23.4 ± 0.31 84.9 ± 0.70 101.8 ± 1.10 6.6 ± 0.64 76.4 ± 1.42 
57 44.5 ± 4.0 54.2 ± 5.3  14.5 ± 1.66 100.2 ± 0.09 100.4 ± 1.36 43.1 ± 3.21 58.0 ± 1.26 
aPapp (nm/s): > 50, high;10-50, medium;< 10, low; caffeine PA-B reference control, 206 ± 35 nm/s; cimetidine PA-B and PB-A 
reference control, 1.1 ± 0.1 and 21.3 ± 3.4 nm/s, respectively. 
 
 
Caco-2 Cell Permeability. The intestinal permeability of compounds 18, 20, 55 and 57 was 
evaluated in the human Caco-2 model in comparison with caffeine (high permeability) and cimetidine 
(low permeability, Pgp substrate). The apparent permeability (Papp) of 18, 20, 55 or 57 from A (apical) 
to B (basolateral) side together with B to A was measured in order to predict the absorption from the 
lumen of the gut and potential efflux phenomena. Compound 20 showed the highest permeability in 
both A→B (Papp = 132.5 nm/s) and B→A (Papp = 133.2 nm/s) directions. Compounds 18, 55 and 57 
showed medium-high permeability (Table 5). None of the compounds tested showed efflux phenomena 
(i.e., ratio between Papp B→A and A→B < 2). 
CYP450 Inhibition. To assess further the safety of compounds 18, 20, 55 and 57, we carried out 
CYP inhibition assay. CYP inhibition can cause drug-drug interactions by increasing concentrations to 
other drugs to toxic levels. The inhibition of the enzymatic activity of human cloned P450 isoforms 
CYP1A2, CYP2C19, CYP2C9, CYP2D6 and CYP3A4 was measured using specific substrates for each 
isoform that produced a fluorescent metabolite upon CYP metabolism. Compounds 18, 20, 55 and 57 at 
1 M were weak inhibitors of the isoforms CYP1A2 and CYP2D6. For these isoforms, inhibition was 
<50%, ranging from <5% (20 in CYP1A2 and CYP2D6 isoforms) to 43% (57 in CYP2D6 isoform). 
The isoform CYP3A4 was inhibited by 20, 55 and 77 by 51%, 76% and 57%, respectively; CYP2C19 
and CYP2C9 were inhibited to a greater extent by 18, 20, 55 and 57. 
 
CONCLUSION 
We synthesized 71 new arylthioindole/aroylindole compounds as potential anticancer agents 
having different (hetero)cyclic substituents at indole position 2. Several new ATIs inhibited tubulin 
polymerization with IC50s ranging from <1.0 to 2.0 µM, and six compounds yielded submicromolar 
IC50’s. These compounds inhibited the growth of human MCF-7 cells, and five of them inhibited the 
growth of these cells with low nM IC50’s. ATI 18 strongly inhibited MCF-7 cell growth (IC50 = 1.0 
nM) and was uniformly active in a larger panel of cancer cells. Compound 18 was superior to reference 
compounds 1 and 2 and ATIs 3-6.19 ATIs 18, 20, 55 and 57 were more potent than 1, 2, VRB, VBL 
and PTX in two MDR cell lines, the Pgp overexpressing NCI-ADR-RES line and the Messa/Dx5 line. 
Compounds 18 and 57 arrested cell cycle progression at the G2/M phase. Compound 18 was a potent 
inhibitor of cell cycle progression at 20 nM, strongly inhibited MT polymerization, and induced 
effective mitotic arrest and cell death, while 57 showed somewhat weaker effects. Compounds 18 and 
57 elicited dose- and time-dependent inhibition of U87MG cell growth and induced mitochondrial 
membrane potential collapse, a hallmark of early apoptosis. The compounds also evoked significant 
ROS generation in GBM cells. At 15 mg/kg intravenous dosage, both compounds 18 and 57 exerted 
initial vascular disrupting effects in a tumor model of liver rhabdomyosarcomas. In a microsomal 
stability assay, compound 18 showed the highest metabolic stability with both human and mouse liver 
microsomes of all the ATIs examined. The higher solubility in aqueous pH 7.4 buffer of compound 18 
(64.5 M) could explain its greater inhibitory effects on cell growth (MCF-7 cells, IC50 = 1.0 nM) 
among compounds with comparable inhibitory effects on tubulin assembly. In conclusion, we 
succeeded in improving the ATI class of cancer agents through the synthesis of new compounds. 
Compounds 18 and 57 proved to be superior to 5, the reference ATI of the previous series,19 in the 
whole cancer cell panel, including two MDR cell lines. Derivative 18 showed higher metabolic stability 
than 5 in human liver microsomes (48.6 % remaining), showed the highest water solubility and 
displayed medium-high Caco-2 cell permeability. The present results highlight the therapeutic potential 
of the ATI class as anticancer agents and prompt their further development. 
  
 
EXPERIMENTAL SECTION 
Microwave-assisted reactions were performed on a CEM Discover SP single mode reactor, 
controlling the instrument settings with PC-running CEM Synergy 1.49 software. Closed vessel 
experiments were carried out in capped microwave-dedicated vials (10 mL) with cylindrical stirring bar 
(length 8 mm, diameter 3 mm). Open vessel experiments were carried out in 100 mL round-bottom 
flasks equipped with a Dimroth reflux condenser and a cylindrical stirring bar (length 20 mm, diameter 
6 mm). Stirring, temperature, irradiation power, PowerMAX (simultaneous cooling-while-heating), 
ActiVent (simultaneous venting-while-heating), ramp and hold times were set as indicated. 
Temperature of the reaction was monitored by a built-in infrared sensor. After completion of the 
reaction, the mixture was cooled to 25 °C via air-jet cooling. Melting points (mp) were determined on a 
Stuart Scientific SMP1 apparatus and are uncorrected. Infrared spectra (IR) were run on a Perkin Elmer 
SpectrumOne FT-ATR spectrophotometer. Band position and absorption ranges are given in cm-1. 
Proton nuclear magnetic resonance (1H NMR) spectra were recorded on a Bruker 400 MHz FT 
spectrometer in the indicated solvent and corresponding fid files processed by MestreLab Research 
S.L. MestreReNova 6.2.1-769 software. Chemical shifts are expressed in δ units (ppm) from 
tetramethylsilane. Column chromatography was performed on columns packed with alumina from 
Merck (70-230 mesh) or silica gel from Macherey-Nagel (70-230 mesh). Aluminum oxide thin layer 
chromatography (TLC) cards from Fluka (aluminum oxide precoated aluminum cards with fluorescent 
indicator visualizable at 254 nm) and silica gel TLC cards from Macherey-Nagel (silica gel precoated 
aluminum cards with fluorescent indicator visualizable at 254 nm) were used for TLC. Developed 
plates were visualized by a Spectroline ENF 260C/FE UV apparatus. Organic solutions were dried over 
anhydrous Na2SO4. Evaporation of the solvents was carried out on a Buchi Rotavapor R-210 equipped 
with a Buchi V-850 vacuum controller and a Buchi V-700 or V-710 vacuum pumps. All reagents and 
solvents are commercially available and were used as purchased, without further purification. 
Elemental analyses of the compounds were found within ±0.4% of the theoretical values. The purity of 
tested compounds was >95%. 
2-(1H-Imidazol-1-yl)-1H-indole (80),21 2-(1H-Pyrazol-3-yl)-1H-indole (99),22 2-iodo-1H-indole 
(106),23 2-(1H-pyrrol-2-yl)-1H-indole (109),25 2-(1-(phenylsulfonyl)-1H-pyrrol-3-yl)-1H-indole 
(110),19 2-(furan-2-yl)-1H-indole (111),19 2-(furan-3-yl)-1H-indole (112),19 1H-indole-2-carbaldehyde 
(115),26 2-(1-(2-Phenylhydrazono)ethyl)pyridine (130),29 3-(1-(2-phenylhydrazono)ethyl)pyridine 
(131),29 4-(1-(2-phenylhydrazono)ethyl)pyridine (132),29 and 1-(1-(naphthalen-2-yl)ethylidene)-2-
phenylhydrazine (133)29 were synthesized according to the indicated Lit. 2-Phenyl-1H-indole (84), 1H-
indole-2-carboxylic acid (105), 2-bromo-1-(2-methoxyphenyl)ethanone (119) and 2-bromo-1-(3-
methoxyphenyl)ethanone (120) were purchased from Sigma-Aldrich. 
 
Arylthio-1H-indoles. General Procedure for the Preparation of Compounds 17, 18, 20, 27, 33, 
34, 38, 39, 41, 43, 45-47, 53, 55, 57, 73, 75 and 77. Example. 2-(1H-Imidazol-2-yl)-3-((3,4,5-
trimethoxyphenyl)thio)-1H-indole (17). 2-(1H-Imidazol-2-yl)-1H-indole (79) (0.044 g, 0.00024 mol) 
was added to a suspension of NaH (0.014 g, 0.00036 mol; 60% dispersion in mineral oil) in anhydrous 
DMF (2 mL). After 10 min, bis(3,4,5-trimethoxyphenyl)disulfide (0.1 g, 0.000264 mol) was added, and 
the reaction mixture was placed into the microwave cavity (closed vessel mode, Pmax = 250 PSI). A 
starting microwave irradiation of 150 W was used, the temperature being ramped from 25 to 110 °C 
while stirring. Once 110 °C was reached, taking about 1 min, the reaction mixture was held at this 
temperature for 2 min. The reaction mixture was quenched on crushed ice and extracted with ethyl 
acetate. The organic layer was washed with brine, dried and filtered. Removal of the solvent gave a 
residue that was purified by column chromatography (silica gel, ethyl acetate:n-hexane = 7:3 as eluent) 
to furnish 17 (0.02 g, 22%), mp 135-140 °C (from ethanol). 1H NMR (CDCl3):  3.62 (s, 6H), 3.76 (s, 
3H), 6.38 (s, 2H), 7.14-7.26 (m, 4H), 7.36-7.38 (m, 1H), 7.63 (d, J = 7.9 Hz, 1H), 11.01 (broad s, 
disappeared on treatment with D2O, 1H) 11.58 ppm (broad s, disappeared on treatment with D2O, 1H). 
IR:  2923, 3345 cm-1. Anal. (C20H19N3O3S (381.45)) C, H, N, S. 
2-(1H-Imidazol-1-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (18). Synthesized as 17, 
starting from 80.21 Yield 77%, mp 193-197 °C (from ethanol). 1H NMR (DMSO-d6):  3.57 (s, 6H), 
3.58 (s, 3H), 6.31 (s, 2H), 7.17-7.21 (m, 2H), 7.26-7.30 (m, 1H), 7.49-7.55 (m, 2H), 7.68-7.69 (m, 1H), 
8.14-7.15 (m, 1H), 12.23 ppm (broad s, disappeared on treatment with D2O, 1H). 13C NMR (DMSO-
d6): δ 56.33, 60.48, 91.97, 103.95, 112.62, 119.17, 120.49, 121.66, 123.68, 129.27, 129.77, 132.91, 
133.81,136.2, 136.23, 137.78, 153.79 ppm. IR:  2930 cm-1. Anal. (C20H19N3O3S (381.45)) C, H, N, S. 
2-(1H-1,2,4-Triazol-1-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (20). Synthesized as 17, 
starting from 81. Yield 34%, mp 140-145 °C (from ethanol). 1H NMR (DMSO-d6):  3.58 (s, 9H), 6.37 
(s, 2H), 7.21 (t, J = 7.7 Hz, 1H), 7.31 (t, J = 8.0 Hz, 1H), 7.52-7.58 (m, 2H), 8.41 (s, 1H), 9.12 (s, 1H), 
12.80 ppm (broad s, disappeared on treatment with D2O, 1H). 13C NMR (DMSO-d6): δ 56.32, 60.47, 
93.24, 104.45, 113.01, 119.50, 121.78, 124.14, 128.78, 132.15, 134.11, 135.32, 136.38, 145.67, 153.04, 
153.75 ppm. IR:  3354 cm-1. Anal. (C19H18N4O3S (382.44)) C, H, N, S. 
2-(3-((3,4,5-Trimethoxyphenyl)thio)-1H-indol-2-yl)thiazole (27). Synthesized as 17, starting from 
81. Yield 10%, mp 160-165 °C (from ethanol). 1H NMR (CDCl3):  3.65 (s, 6H), 3.77 (s, 3H), 6.41 (s, 
2H), 7.19-7.23 (m, 1H), 7.31-7.35 (m, 1H), 7.43-7.45 (m, 2H), 7.72 (dd, J = 0.8 and 7.9 Hz, 1H), 7.90 
(d, J = 3.2 Hz, 1H), 9.87 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3339 cm-1. Anal. 
(C20H18N2O3S2 (379.47)) C, H, N, S. 
2-(4,5-Dihydro-1H-imidazol-2-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (33). Synthesized 
as 17, starting from 83. Yield 8%, mp 150-155 °C (from ethanol). 1H NMR (CDCl3):  3.64 (s, 6H), 
3.76 (s, 3H), 3.92 (m, 4H), 6.33 (s, 2H), 7.15 (t, J = 7.1 Hz, 1H), 7.32 (t, J = 7.0 Hz, 1H), 7.49 (d, J = 
8.3 Hz, 1H), 7.61 (d, J = 8.1 Hz, 1H), 8.31 (broad s, disappeared on treatment with D2O, 1H), 12.10 
ppm (broad s, disappeared on treatment with D2O, 1H). IR:  2852, 2921 cm-1. Anal. (C20H21N3O3S 
(383.46)) C, H, N, S. 
2-Phenyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (34). Synthesized as 17, starting from 84. 
Yield 3%, mp 158-160 °C (from ethanol). 1H NMR (CDCl3):  3.64 (s, 6H), 3.78 (s, 3H), 6.37 (s, 2H), 
7.18-7.22 (m, 1H), 7.27-7.30 (m, 2H), 7.41-7.50 (m, 3H), 7.69 (d, J = 7.9 Hz, 1H), 7.80-7.82 (m, 2H), 
8.56 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3329 cm-1. Anal. (C23H21NO3S 
(391.48)) C, H, N, S. 
2-(4-Chlorophenyl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (38). Synthesized as 17, starting 
from 85. Yield 11%, mp 190-195 °C (from ethanol). 1H NMR (CDCl3):  3.64 (s, 6H), 3.78 (s, 3H), 
6.34 (s, 2H), 7.19-7.23 (m, 1H), 7.29-7.31 (m, 1H), 7.43-7.46 (m, 3H), 7.68-7.70 (m, 1H), 7.72-7.75 
(m, 2H), 8.59 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3335 cm-1. Anal. 
(C23H20ClNO3S (425.93)) C, H, N, Cl, S. 
2-(2-Fluorophenyl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (39). Synthesized as 17, starting 
from 86. Yield 39% mp 175-180 °C (from toluene). 1H NMR (DMSO-d6):  3.54 (s, 6H), 3.56 (s, 3H), 
6.26 (s, 2H), 7.13 (t, J = 7.6 Hz, 1H), 7.24 (t, J = 7.8 Hz, 1H), 7.33-7.42 (m, 2H), 7.49-7.54 (m, 3H), 
7.65 (t, J = 7.5 Hz, 1H), 12.07 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3342 cm-1. 
Anal. (C23H20FNO3S (409.47)) C, H, N, F, S. 
2-(3-Fluorophenyl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (41). Synthesized as 17, starting 
from 87. Yield 65%, mp 180-185 °C (from toluene). 1H NMR (DMSO-d6):  3.59 (s, 3H), 3.64 (s, 6H), 
6.79 (s, 2H), 7.07-7.35 (m, 5H), 7.45-7.48 (m, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.95 (d, J = 7.8 Hz, 1H), 
12.27 (broad s, disappeared on treatment with D2O, 1H). IR:  1571, 3187 cm-1. Anal. (C24H20FNO4 
(405.42)) C, H, N, F, S. 
2-(4-Fluorophenyl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (43). Synthesized as 17, starting 
from 88. Yield 37%, mp 170-175 °C (from toluene). 1H NMR (DMSO-d6):  3.53 (s, 6H), 3.57 (s, 3H), 
6.30 (s, 2H), 7.12 (t, J = 7.0 Hz, 1H), 7.23 (t, J = 7.4 Hz, 1H), 7.38 (t, J = 8.9 Hz, 2H), 7.49 (t, J = 7.2 
Hz, 2H), 7.90-7.93 (m, 2H), 12.09 (broad s, disappeared on treatment with D2O, 1H). IR:  3318 cm-1. 
Anal. (C23H20FNO3S (409.47)) C, H, N, F, S. 
2-(2-Methoxyphenyl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (45). Synthesized as 17, 
starting from 89. Yield 5%, mp 160-165 °C (from ethanol). 1H NMR (CDCl3):  3.64 (s, 6H), 3.77 (s, 
3H), 3.92 (s, 3H), 6.35 (s, 2H), 7.04-7.08 (m, 2H), 7.15-7.19 (m, 1H), 7.25-7.29 (m, 1H), 7.36-7.40 (m, 
1H), 7.45-7.47 (m, 1H), 7.67-7.69 (m, 1H), 7.97-7.99 (m, 1H), 9.40 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR:  3338 cm-1. Anal. (C24H23NO4S (421.51)) C, H, N, S. 
2-(3-Methoxyphenyl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (46). Synthesized as 17,  
starting from 90. Yield 4%, mp 192-194 °C (from ethanol). 1H NMR (CDCl3):  3.63 (s, 6H), 3.75 (s, 
3H), 3.76 (s, 3H), 6.36 (s, 2H), 6.93-6.96 (m, 1H), 7.18-7.21 (m, 1H), 7.25-7.40 (m, 4H), 7.44-7.46 (m, 
1H), 7.69-7.71 (m, 1H), 8.57 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3333 cm-1. 
Anal. (C24H23NO4S (421.51)) C, H, N, S. 
2-(4-Methoxyphenyl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (47). Synthesized as 17, 
starting from 91. Yield 8%, mp 165-170 °C (from ethanol). 1H NMR (CDCl3):  3.63 (s, 6H), 3.78 (s, 
3H), 3.85 (s, 3H), 6.37 (s, 2H), 6.97-6.99 (m, 2H), 7.17-7.23 (m, 2H), 7.41-7.43 (m, 1H), 7.66-7.74 (m, 
3H), 8.68 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3324 cm-1. Anal. (C24H23NO4S 
(421.51)) C, H, N, S. 
2-(Pyridin-2-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (53). Synthesized as 17, starting 
from 92. Yield 26% as an oil. 1H NMR (CDCl3):  3.63 (s, 6H), 3.76 (s, 3H), 6.39 (s, 2H), 7.18 (t, J = 
7.1 Hz, 1H), 7.24-7.27 (m, 2H), 7.45 (d, J = 8.1 Hz, 1H), 7.70-7.77 (m, 2H), 8.63-8.64 (m, 1H), 8.73 
(d, J = 8.1 Hz, 1H), 10.23 ppm (broad s, disappeared on treatment with D2O, 1H). IR: 2828, 2933, 
3003, 3056 cm-1. Anal. (C22H20N2O3S (392.47)) C, H, N, S. 
2-(Pyridin-3-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (55). Synthesized as 17, starting 
from 93. Yield 20%, mp 188-191 °C (from ethanol). 1H NMR (CDCl3):  3.65 (s, 6H), 3.76 (s, 3H), 
6.33 (s, 2H), 7.22 (m, 1H), 7.31 (m, 1H), 7.37-7.41 (m 1H), 7.48 (d, J = 8.1 Hz, 1H), 7.70 (d, J = 7.6 
Hz, 1H), 8.16-8.17 (m, 1H), 8.62 (m, 1H), 9.02 (m, 1H), 9.26 ppm (broad s, disappeared on treatment 
with D2O, 1H). 13C NMR (DMSO-d6): δ 56.28, 60.48, 98.8, 103.33, 112.63, 119.31, 121.21, 123.66, 
124.12, 127.75, 130.72, 133.85, 135.99, 136.82, 139.7, 149.19, 149.68, 153.77 ppm. IR: 2923, 3674 
cm-1. Anal. (C22H20N2O3S (392.47)) C, H, N. 
2-(Pyridin-4-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (57). Synthesized as 17, starting 
from 94. Yield 60% as a yellow solid, mp 215-218 °C (from ethanol). 1H NMR (DMSO-d6):  3.53 (s, 
6H), 3.57 (s, 3H), 6.32 (s, 2H), 7.14-7.18 (m, 1H), 7.27-7.31 (m, 1H), 7.53-7.57 (m, 2H), 7.92 (dd, J = 
1.7 and 4.5 Hz, 2H), 8.71 (dd, J = 1.6 and 4.5 Hz, 2H), 12.36 ppm (broad s, disappeared on treatment 
with D2O, 1H). 13C NMR (DMSO-d6): δ 56.27, 60.47, 100.49, 103.60, 112.82, 119.63, 121.38, 122.5, 
124.25, 130.89, 133.39, 135.99, 136.92, 138.76, 139.02, 150.52, 153.8 ppm. -1. Anal. 
(C22H20N2O3S (392.47)) C, H, N. 
2-Cyclobutyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (73). Synthesized as 17, starting from 
95. Yield 56%, mp 149-153 °C (from ethanol). 1H NMR (DMSO-d6):  1.85-1.92 (m, 1H), 1.98-2.10 
(m, 1H), 2.23-2.28 (m, 2H), 2.28-2.30 (m, 2H), 2.57 (s, 9H), 3.94-4.03 (m, 1H), 6.27 (s, 2H), 7.01-7.05 
(m, 1H), 7.11-7.15 (m, 1H), 7.38 (d, J = 7.8 Hz, 1H), 7.43 (d, J = 8.0 Hz, 1H), 11.74 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR:  3361 cm-1. Anal. (C21H23NO3S (369.48)) C, H, N, S. 
2-Cyclopentyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (75). Synthesized as 17, starting from 
96. Yield 56%, mp 178-183 °C (from ethanol). 1H NMR (DMSO-d6):  1.66-1.68 (m, 2H), 1.17-1.85 
(m, 4H), 1.95-1.98 (m, 2H), 3.52-3.54 (m, 1H), 3.56 (s, 6H), 3.57 (s, 3H), 6.28 (s, 2H), 7.0-7.04 (m, 
1H), 7.09-7.13 (m, 1H), 7.36-7.41 (m, 2H), 11.51 ppm (broad s, disappeared on treatment with D2O, 
1H). IR:  3331 cm-1. Anal. (C22H25NO3S (383.50)) C, H, N, S. 
2-Cyclohexyl-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (77). Synthesized as 17, starting from 
97. Yield 48%, mp 214-219 °C (from ethanol). 1H NMR (DMSO-d6):  1.24-1.42 (m, 3H), 1.66-1.83 
(m, 7H), 3.09-3.17 (m, 1H), 3.56 (s, 6H), 3.57 (s, 3H), 6.28 (s, 2H), 7.0-7.02 (m, 1H), 7.09-7.13 (m, 
1H), 7.35-7.41 (m, 2H), 11.52 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3327 cm-1. 
Anal. (C23H27NO3S (397.53)) C, H, N, S. 
General Procedure for the Preparation of Compounds 14, 16, 37, 48, 59, 62 and 72. Example. 
2-(1H-Pyrazol-4-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (14). 2-(1H-Pyrazol-4-yl)-1H-
indole (98) (0.08 g, 0.00044 mol) was added to an ice-cooled suspension of NaH (0.058 g, 0.00145 
mol; 60% dispersion in mineral oil) in anhydrous DMF (3 mL) under an Ar stream. After 15 min, 
bis(3,4,5-trimethoxyphenyl)disulfide (0.21 g, 0.00053 mol) was added, and the reaction mixture was 
heated at 60 °C for 12 h under an Ar stream. After cooling, the reaction mixture was quenched on 
crushed ice and extracted with ethyl acetate. The organic layer was washed with brine, dried and 
filtered. Removal of the solvent gave a residue that was purified by column chromatography (silica gel, 
ethyl acetate:n-hexane = 7:3) to furnish 14 (0.1 g, 59%), mp 178-182 °C (from ethanol). 1H NMR 
(DMSO-d6):  3.53 (s, 6H), 3.57 (s, 3H), 6.33 (s, 2H), 7.06-7.10 (m, 1H), 7.15-7.19 (m, 1H), 7.44-7.46 
(m, 2H), 8.23 (m, 2H), 11.88 (broad s, disappeared on treatment with D2O, 1H), 13.17 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR:  3158, 3291 cm-1. Anal. (C20H19N3O3S (381.45)) C, H, 
N, S. 
2-(1H-Pyrazol-3-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (16). Synthesized as 14, starting 
from 99.22 Yield 35%, mp 194-197 °C (from ethanol). 1H NMR (DMSO-d6):  3.51 (s, 6H), 3.55 (s, 
3H), 6.35 (s, 2H), 6.97-6.98 (m, 1H), 7.07 (t, J = 7.6 Hz, 1H), 7.17 (t, J = 7.9 Hz, 1H), 7.46-7.49 (m, 
2H), 7.83 (s, 1H), 11.97 (broad s, disappeared on treatment with D2O, 1H), 13.23 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR:  2936, 3348 cm-1. Anal. (C20H19N3O3S (381.45)) C, H, 
N, S. 
2-(p-Tolyl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (37). Synthesized as 14, starting from 
100. Yield 72%, mp 168-171 °C (from ethanol). 1H NMR (DMSO-d6):  2.36 (s, 3H), 3.52 (s, 6H), 
3.56 (s, 3H), 6.29 (s, 2H), 7.09-7.13 (m, 1H), 7.19-7.23 (m, 1H), 7.32-7.34 (m, 2H), 7.47-7.51 (m, 2H), 
7.78-7.80 (m, 2H), 12.02 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3344 cm-1. 
Anal. (C24H23NO3S (405.51)) C, H, N, S. 
2-(3-Isopropoxy-4-methoxyphenyl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (48). 
Synthesized as 14, starting from 101. Yield 53%, mp 110-113 °C (from ethanol). 1H NMR (CDCl3):  
1.29 (d, J = 6.1 Hz, 6H), 3.65 (s, 6H), 3.77 (s, 3H), 3.90 (s, 3H), 4.35 (m, 1H), 6.36 (s, 2H), 6.97 (d, J = 
8.4 Hz, 1H), 7.19-7.29 (m, 3H), 7.41 (m, 1H), 7.44-7.46 (m, 1H), 7.70-7.72 (m, 1H), 8.56 ppm (broad 
s, disappeared on treatment with D2O, 1H). IR:  3337 cm-1. Anal. (C27H29NO5S (479.59)) C, H, N, S. 
2-(Naphthalen-1-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (59). Synthesized as 14, starting 
from 102. Yield 44%, mp 227-230 °C (from ethanol). 1H NMR (CDCl3):  3.56 (s, 6H), 3.71 (s, 3H), 
6.30 (s, 2H), 7.22-7.26 (m, 1H), 7.29-7.33 (m, 1H), 7.39-7.55 (m, 4H), 7.61 (dd, J = 1.2 and 7.1 Hz, 
1H), 7.74-7.76 (m, 1H), 7.82-7.84 (m, 1H), 7.90-7.95 (m, 2H), 8.59 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR:  3229 cm-1. Anal. (C27H23NO3S (441.54)) C, H, N, S. 
2-(Naphthalen-2-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (62). Synthesized as 14, starting 
from 103. Yield 44%, mp 157-160 °C (from ethanol). 1H NMR (CDCl3):  3.65 (s, 6H), 3.79 (s, 3H), 
6.42 (s, 2H), 7.22-7.34 (m, 2H), 7.50-7.56 (m, 3H), 7.74-7.75 (m, 1H), 7.88-7.90 (m, 2H), 7.93-8.00 
(m, 2H), 8.25 (m, 1H), 8.71 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3318 cm-1. 
Anal. (C27H23NO3S (441.54)) C, H, N, S. 
2-((1,1'-Biphenyl)-4-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (72). Synthesized as 14, 
starting from 104. Yield 52%, mp 210-215 °C (from ethanol). 1H NMR (DMSO-d6):  3.54 (s, 6H), 
3.57 (s, 3H), 6.33 (s, 2H), 7.11-7.15 (m, 1H), 7.23-7.25 (m, 1H), 7.38-7.42 (m, 1H), 7.48-7.54 (m, 4H), 
7.75-7.77 (m, 2H), 7.84-7.86 (m, 2H), 8.01-8.03 (m, 2H), 12.14 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR:  3329 cm-1. Anal. (C29H25NO3S (467.58)) C, H, N, S. 
2-(3-((3,4,5-Trimethoxyphenyl)thio)-1H-indol-2-yl)-4,5-dihydroxazole (28). 2-Bromoethylamine 
hydrobromide (0.63 g, 0.0031 mol) was added to a solution of 3-((3,4,5-trimethoxyphenyl)thio)-1H-
indole-2-carboxylic acid (107) (1.0 g, 0.0028 mol), triethylamine (0.85 g, 1.2 mL,  0.0084 mol) and 
BOP reagent (1.24 g, 0.0028 mol) in anhydrous DMF (15 mL). The reaction mixture was stirred at 25 
°C for 2 h and then diluted with water and extracted with ethyl acetate. The organic layer was washed 
with brine, dried and filtered. Removal of the solvent gave a residue that was purified by column 
chromatography (silica gel, ethyl acetate:n-hexane = 7:3 as eluent) to furnish 28 (0.31 g, 30%), mp 
190-195 °C (from ethanol). 1H NMR (DMSO-d6):  3.55 (s, 6H), 3.56 (s, 3H), 4.00 (t, J = 9.7 Hz, 2H), 
4.43 (t, J = 9.5 Hz, 2H), 6.42 (s, 2H), 7.07-7.11 (m, 1H), 7.23-7.27 (m, 1H), 7.43-7.49 (m, 2H), 12.21 
ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3198 cm-1. Anal. (C20H20N2O4S (384.45)) 
C, H, N, S. 
2-(3-((3,4,5-Trimethoxyphenyl)thio)-1H-indol-2-yl)oxazole (31). A mixture of 2-iodo-3-((3,4,5-
trimethoxyphenyl)thio)-1H-indole (108) (0.1 g, 0.00023 mol), 2-(tributylstannyl)oxazole (0.25 g, 0.1 
ml, 0.00069 mol), P(Cy)3 (0.0064 g, 0.000023 mol) in anhydrous DMF (2 mL) was degassed for 10 
min. Pd2(dba)3 (0.01 g, 0.000011 mol) was added, and the reaction mixture was placed into the 
microwave cavity (closed vessel mode, Pmax = 250 PSI). A starting microwave irradiation of 150 W 
was used, the temperature being ramped from 25 °C to 150 °C while stirring. Once 150 °C was 
reached, taking about 2 min, the reaction mixture was held at this temperature for 10 min. The reaction 
was quenched on a mixture of a saturated aqueous solution of potassium carbonate (20 mL) and ethyl 
acetate while stirring for 30 min. The organic layer was separated and washed with brine, dried and 
filtered. Removal of the solvent gave a residue that was purified by column chromatography (silica gel, 
ethyl acetate:n-hexane = 1:3 as eluent) to furnish 31 (0.03, 35%), mp 80-83 °C (from ethanol). 1H NMR 
(DMSO-d6):  3.56 (s, 6H), 3.57 (s, 3H), 6.38 (s, 2H), 7.06-7.10 (m, 1H), 7.16-7.20 (m, 1H), 7.40-7.52 
(m, 3H), 7.76-7.77 (m, 1H), 11.66 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3340 
cm-1. Anal. (C20H18N2O4S (382.43)) C, H, N, S. 
6-(3-((3,4,5-Trimethoxyphenyl)thio)-1H-indol-2-yl)quinoline (66). A mixture of 108 (0.1 g, 
0.00023 mol), 6-quinolineboronic acid pinacol ester (0.076 g, 0.0003 mol) and potassium phosphate 
(0.14 g, 0.00068 mol) in anhydrous DMF (10 mL) was degassed for 30 min. Pd(dppf)Cl2.CH2Cl2 
(0.0054 g, 0.0000066 mol; complex with dichloromethane (1:1), Pd 13%) was added under an Ar 
stream, and the reaction mixture was heated at 110 °C for 12 h. After cooling, the reaction mixture was 
diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried and 
filtered. Removal of the solvent gave a residue that was purified by column chromatography (silica gel, 
ethyl acetate:n-hexane = 8:2 as eluent) to furnish 66 as a slurry (0.07 g, 70%). 1H NMR (DMSO-d6):  
3.52 (s, 6H), 3.55 (s, 3H), 6.35 (s, 2H), 7.14-7.16 (m, 1H), 7.25-7.28 (m, 1H), 7.54-7.61 (m, 3H), 8.15 
(d, J = 8.8 Hz, 1H), 8.32 (dd, J = 2.0 and 8.8 Hz, 1H), 8.42 (d, J = 7.3 Hz, 1H), 8.47 (d, J = 1.8 Hz, 
1H), 8.95 (dd, J = 1.7 and 4.2 Hz, 1H), 12.29 ppm (broad s, disappeared on treatment with D2O, 1H). 
IR:  2922, 3305 cm-1. Anal. (C26H22N2O3S (442.53)) C, H, N, S. 
3-((3,4,5-Trimethoxyphenyl)thio)-1H,1'H-2,5'-bisindole (67). Synthesized as 66, starting from 
108 and 1-Boc-indole-5-boronic acid pinacol ester. Yield 26% as a slurry. 1H NMR (CDCl3):  3.64 (s, 
6H), 3.79 (s, 3H), 6.41 (s, 2H), 6.61-6.62 (m, 1H), 7.21-7.28 (m, 3H), 7.45-7.47 (m, 2H), 7.64-7.71 (m, 
2H), 8.05-8.06 (m, 1H), 8.32 (broad s, disappeared on treatment with D2O, 1H), 8.65 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR:  2963, 2918, 3350 cm-1. Anal. (C25H22N2O3S (430.52)) 
C, H, N, S. 
3-((3,4,5-Trimethoxyphenyl)thio)-1H,1'H-2,2'-bisindole (68). A mixture of 108 (0.15 g, 0.00034 
mol), 2-(triethylstannyl)-1H-indole-1-carboxylic acid24 (0.25 g, 0.000683 mol) and ethanol (5 mL) was 
degassed for 30 min. PdCl2(PPh3)2 (0.021 g, 0.000031 mol) was added under an Ar stream, and the 
reaction mixture was heated at 78 °C for 48 h. After cooling, the mixture was filtered through a pad of 
celite, then diluted with water and extracted with ethyl acetate. The organic layer was washed with 
brine, dried and filtered. Removal of the solvent gave a residue that was purified by column 
chromatography (silica gel, ethyl acetate:n-hexane = 1:2 as eluent) to furnish 68 (0.03 g, 20%), mp 
220-225 °C (from ethanol). 1H NMR (DMSO-d6):  3.52 (s, 6H), 3.55 (s, 3H), 6.39 (s, 2H), 7.02-7.06 
(m, 1H), 7.13-7.18 (m, 3H), 7.22-7.26 (m, 1H), 7.49-7.55 (m, 3H), 7.59-7.61 (m, 1H), 11.37 (broad s, 
disappeared on treatment with D2O, 1H), 12.02 ppm (broad s, disappeared on treatment with D2O, 1H). 
IR:  3326, 3388 cm-1. Anal. (C25H22N2O3S (430.52)) C, H, N, S. 
2-(Benzofuran-2-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (69). A mixture of 108 (0.1 g, 
0.00023 mol), 2-benzofuranylboronic acid (0.29 g, 0.0018 mol) and potassium carbonate (0.28 g, 0.02 
mol) in 1,4-dioxane (12 mL) containing water (2 mL) was degassed for 30 min. Pd(OCOMe)2 (0.052 g, 
0.00234 mol) was added under an Ar stream, and the reaction mixture was heated at 100 °C for 24 h. 
After cooling, the mixture was diluted with water and extracted with ethyl acetate. The organic layer 
was washed with brine, dried and filtered. Removal of the solvent gave a residue that was purified by 
column chromatography (silica gel, ethyl acetate:n-hexane = 1:2 as eluent) to furnish 69 (0.11 g, 88%), 
mp 190-195 °C (from ethanol). 1H NMR (DMSO-d6):  3.54 (s, 6H), 3.56 (s, 3H), 6.42 (s, 2H), 7.14-
7.18 (m, 1H), 7.27-7.33 (m, 2H), 7.37-7.42 (m, 1H), 7.54-7.57 (m, 2H), 7.64-7.67 (m, 2H), 7.75-7.76 
(m, 1H), 12.49 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3338 cm-1. Anal. 
(C25H21NO4S (431.50)) C, H, N, S. 
2-(Benzo[b]thiophen-2-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (70). A mixture of 108 
(0.1 g, 0.00023 mol), benzo[b]thien-2-ylboronic acid (0.04 g, 0.000225 mol) and 1 M potassium 
carbonate (0.6 mL) in THF (5 mL) was degassed for 30 min. Pd(PPh3)4 (0.01 g, 0. 009 mmol) was 
added under an Ar stream, and the reaction mixture was heated at 60 °C for 24 h. After cooling, the 
mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with 
brine, dried and filtered. Removal of the solvent gave a residue that was purified by column 
chromatography (silica gel, dichloromethane:ethyl acetate = 99:1 as eluent) to furnish 70 (0.01 g, 
10%), mp 220-225 °C (from ethanol). 1H NMR (CDCl3):  3.66 (s, 6H), 3.78 (s, 3H), 6.44 (s, 2H), 
7.21-7.23 (m, 1H), 7.28-7.39 (m, 3H), 7.46 (d, J = 7.6 Hz, 1H), 7.70 (d, J = 7.6 Hz, 1H), 7.80-7.86 (m, 
3H), 8.83 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3303 cm-1. Anal. (C25H21NO3S2 
(447.57)) C, H, N, S. 
2-(Benzo[b]thiophen-3-yl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (71). A mixture of 108 
(0.1 g, 0.00023 mol), SPhos (0.0075 g, 0. 0182 mmol), Pd2(dba)3 (0.0042 g, 0. 00454 mmol) and  
potassium carbonate (0.0964 g, 0.000454 mol) was degassed for 30 min. A solution of benzo[b]thien-3-
ylboronic acid (0.061 g, 0.00034 mol) in n-BuOH (2 mL) was added under an Ar stream, and the 
reaction mixture was heated at 100 °C for 12 h. After cooling, the mixture was diluted with water, 
made acidic with 1 M HCl (pH ≈ 3-4) and extracted with ethyl acetate. The organic layer was washed 
with brine, dried and filtered. Removal of the solvent gave a residue that was purified by column 
chromatography (silica gel, ethyl acetate:n-hexane = 1:2 as eluent) to furnish 71 (0.037 g, 36%), mp 
170-174 °C (from ethanol). 1H NMR (DMSO-d6):  3.48 (s, 6H), 3.53 (s, 3H), 6.25 (s, 2H), 7.16-7.18 
(m, 1H), 7.24-7.28 (m, 1H), 7.45-7.47 (m, 2H), 7.53-7.56 (m, 2H), 7.87-7.89 (m, 1H), 8.18 (s, 1H), 
8.09-8.12 (m, 1H), 12.17 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3237 cm-1. 
Anal. (C25H21NO3S2 (447.57)) C, H, N, S. 
2-Methoxy-5-(3-((3,4,5-trimethoxyphenyl)thio)-1H-indol-2-yl)phenol (49). Anhydrous aluminum 
chloride (0.14 g, 0.001 mol) was added to a solution of 48 (0.17 g, 0.00035 mol) in anhydrous 
dichloromethane (10 mL). The reaction mixture was stirred at 25 °C for 1.5 h. After dilution with a 
saturated aqueous solution of ammonium chloride, the mixture was extracted with chloroform. The 
organic layer was washed with brine, dried and filtered. Removal of the solvent gave a residue that was 
purified by column chromatography (silica gel, ethyl acetate:n-hexane = 1:1 as eluent) to furnish 49 
(0.05 g, 35%), mp 110-113 °C (from ethanol). 1H NMR (CDCl3):  3.65 (s, 6H), 3.77 (s, 3H), 3.95 (s, 
3H), 5.69 (s, 1H), 6.36 (s, 2H), 6.94 (d, J = 8.3 Hz, 1H), 7.16-7.20 (m, 1H), 7.24-7.28 (m, 1H), 7.34 
(dd, J = 2.2 and 8.3 Hz, 1H), 7.38 (d, J = 2.2 Hz, 1H), 7.42-7.44 (m, 1H), 7.66-7.68 (m, 1H), 8.49 ppm 
(broad s, disappeared on treatment with D2O, 1H). IR:  2933, 3329 cm-1. Anal. (C24H23NO5S 
(437.51)) C, H, N, S. 
2-(3,4-Dimethoxyphenyl)-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (50). Iodomethane (0.033 
g, 0.01 mL, 0.00023 mol) was added to a mixture of 49 (0.1 g, 0.00023 mol) and anhydrous potassium 
carbonate (0.032 g, 0.00023 mol) in anhydrous DMF (5 mL). The reaction mixture was stirred at 25 °C 
for 2 h, then diluted with water and extracted with ethyl acetate. The organic layer was washed with 
brine, dried and filtered. Removal of the solvent gave a residue that was purified by column 
chromatography (silica gel, ethyl acetate:n-hexane = 1:1 as eluent) to furnish 50 (0.02 g, 20%), mp 
117-118 °C (from ethanol). 1H NMR (CDCl3):  3.65 (s, 6H), 3.77 (s, 3H), 3.78 (s, 3H), 3.94 (s, 3H), 
6.38 (s, 2H), 6.97 (d, J = 8.3 Hz, 1H), 7.19-7.23 (m, 1H), 7.26-7.31 (m, 2H), 7.40 (d, J = 2.1 Hz, 1H), 
7.45-7.47 (m, 1H), 7.70-7.72 (m, 1H), 8.57 ppm (broad s, disappeared on treatment with D2O, 1H). IR: 
 3344 cm-1. Anal. (C25H25NO5S (451.53)) C, H, N, S. 
 Aroyl-1H-indoles. General Procedure for the Preparation of Compounds 7, 15, 19, 54, 56, 58 
and 60. Example. (2-(1H-Pyrrol-2-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (7). 
Methylmagnesium bromide (1.4 mL, 0.0041 mol; 3.0 M in Et2O) was added dropwise over 5 min into a 
mixture of 2-(1H-pyrrol-2-yl)-1H-indole25 (109) (0.5 g, 0.003 mol) and anhydrous ZnCl2 (0.82 g, 0.006 
mol) in anhydrous dichloromethane (20 mL) at 25 °C under an Ar stream. After 1 h, a solution of 3,4,5-
trimethoxybenzoyl chloride (0.76 g, 0.0033 mol) in the same solvent (16 mL) was added dropwise over 
5 min at 25 °C under an Ar stream. After an additional 1 h, SnCl4 (3 mL, 0.003 mol; 1.0 M in 
dichloromethane) was added dropwise, and the reaction mixture stirred at 25 °C for 12 h under an Ar 
stream. The reaction was quenched on crushed ice and extracted with dichloromethane The organic 
layer was washed with brine, dried and filtered. Removal of the solvent gave a residue that was purified 
by column chromatography (silica gel, ethyl acetate:n-hexane = 1:1 as eluent) to furnish 7 (0.03 g, 3%), 
mp 59-62 °C (from toluene). 1H NMR (DMSO-d6):  3.70 (s, 6H), 3.75 (s, 3H), 6.24-6.26 (m, 1H), 
6.84-6.85 (m, 1H), 6.96-7.07 (m, 5H), 7.14-7.18 (m, 1H), 7.43-7.45 (m, 1H), 11.94 (broad s, 
disappeared on treatment with D2O, 1H), 12.15 ppm (broad s, disappeared on treatment with D2O, 1H). 
IR:  cm-1. Anal. (C22H20N2O4 (376.41)) C, H, N. 
(2-(1H-Pyrazol-4-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (15). Synthesized as 7, 
starting from 98. Yield 21%, mp 112-117 °C (from ethanol). 1H NMR (DMSO-d6):  3.65 (s, 6H), 3.71 
(s, 3H), 6.95 (s, 2H), 7.06-7.10 (m, 1H), 7.16-7.20 (m, 1H), 7.44-7.51 (m, 2H), 7.86 (m, 2H), 12.02 
(broad s, disappeared on treatment with D2O, 1H), 13.04 ppm (broad s, disappeared on treatment with 
D2O, 1H). IR:  1634, 2962, 3243 cm-1. Anal. (C21H19N3O4 (377.39)) C, H, N. 
(2-(1H-Imidazol-1-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (19). Synthesized as 7 
starting from 80.21 Yield 26%, mp 210-215 °C (from ethanol). 1H NMR (DMSO-d6):  3.66 (s, 3H), 
3.69 (s, 6H), 6.79 (s, 2H), 6.88-6.89 (m, 1H), 7.24-7.32 (m, 2H), 7.39-7.40 (m, 1H), 7.50-7.52 (m, 1H), 
7.79-7.80 (m, 1H), 7.97-7.99 (m, 1H), 12.66 ppm (broad s, disappeared on treatment with D2O, 1H). 
IR:  1618, 3354 cm-1. Anal. (C21H19N3O4 (377.39)) C, H, N.  
 (2-(Pyridin-2-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (54). Synthesized as 7, 
starting from 92. Yield 67%, mp 65-70 °C (from ethanol). 1H NMR (DMSO-d6):  3.61 (s, 6H), 3.64 
(s, 3H), 6.89 (s, 2H), 7.19-7.21 (m, 1H), 7.26-7.28 (m, 2H), 7.39-7.41 (m, 1H), 7.56-7.58 (m, 1H), 
7.63-7.65 (m, 1H), 7.79-7.81 (m, 1H), 8.55-8.57 (m, 1H), 12.36 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR:  1625, 3241 cm-1. Anal. (C23H20N2O4 (388.42)) C, H, N. 
 (2-(Pyridin-3-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (56). Synthesized as 7, 
starting from 93. Yield 45%, mp 130-135 °C (from ethanol). 1H NMR (DMSO-d6):  3.60 (s, 3H), 3.61 
(s, 6H), 6.82 (s, 2H), 7.21-7.31 (m, 3H), 7.53-7.55 (m, 1H), 7.75-7.78 (m, 1H), 7.96 (d, J = 7.7 Hz, 
1H), 8.44 (dd, J = 1.6 and 4.8 Hz, 1H), 8.56-8.57 (m, 1H), 12.38 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR:  1597, 3094 cm-1. Anal. (C23H20N2O4 (388.42)) C, H, N. 
(2-(Pyridin-4-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (58). Synthesized as 7, 
starting from 94. Yield 10%, mp 50-55 °C (from ethanol). 1H NMR (DMSO-d6):  3.62 (s, 3H), 3.63 
(s, 6H), 6.86 (s, 2H), 7.21-7.25 (m, 1H), 7.29-7.33 (m, 1H), 7.35-7.37 (m, 2H), 7.55-7.57 (m, 1H), 
7.87-7.90 (m, 1H), 8.46-8.47 (m, 2H), 12.43 ppm (broad s, disappeared on treatment with D2O, 1H). 
IR:  1602, 3304 cm-1. Anal. (C23H20N2O4 (388.42)) C, H, N. 
 (2-(Naphthalen-1-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (60). Synthesized as 7, 
starting from 102. Yield 50%, mp 177-179 °C (from ethanol). 1H NMR (CDCl3):  3.40 (s, 6H), 3.64 
(s, 3H), 6.61 (s, 2H), 7.26-7.30 (m, 1H), 7.34-7.36 (m, 1H), 7.37-7.41 (m, 2H), 7.43-7.53 (m, 3H), 7.73 
(d, J = 8.2 Hz, 1H), 7.78-7.83 (m, 1H), 7.94-8.00 (m, 1H), 8.31-8.36 (m, 1H), 8.81 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR:  1605, 3158 cm-1. Anal. (C28H23NO4 (437.49)) C, H, N. 
General Procedure for the Preparation of Compounds 9, 21, 23, 25, 32, 35, 40, 42, 44, 51, 63, 
74, 76 and 78. Example. (2-(1-(Phenylsulfonyl)-1H-pyrrol-3-yl)-1H-indol-3-yl)(3,4,5-
trimethoxyphenyl)methanone (9). A mixture of 2-(1-(phenylsulfonyl)-1H-pyrrol-3-yl)-1H-indole19 
(110) (0.26 g, 0.00082 mol), 3,4,5-trimethoxybenzoyl chloride (0.23 g, 0.00098 mol) and anhydrous 
aluminum chloride (0.13 g, 0.00098 mol) in anhydrous 1,2-dichloroethane (2 mL) was placed into the 
microwave cavity (closed vessel mode, Pmax = 250 PSI). A starting microwave irradiation of 150 W 
was used, the temperature being ramped from 25 °C to 110 °C while stirring. Once 110 °C was 
reached, taking about 1 min, the reaction mixture was held at this temperature for 2 min. The reaction 
mixture was quenched on 1 M HCl/crushed ice and extracted with chloroform. The organic layer was 
washed with brine, dried and filtered. Removal of the solvent gave a residue that was purified by 
column chromatography (silica gel, ethyl acetate:n-hexane = 1:1 as eluent) to furnish 9 (0.27 g, 65%), 
mp 124-126 °C (from ethanol). 1H NMR (DMSO-d6):  3.57 (s, 6H), 3.67 (s, 3H), 6.44 (s, 1H), 6.92 (s, 
2H), 7.07 (t, J = 7.4 Hz, 1H), 7.18 (t, J = 7.4 Hz, 1H), 7.35 (s, 1H), 7.43 (d, J = 7.8 Hz, 1H), 7.49 (d, J 
= 7.9 Hz, 1H), 7.66 (t, J = 7.8 Hz, 2H), 7.76-7.78 (m, 2H), 7.96 (d, J = 7.4 Hz, 2H), 12.04 ppm (broad 
s, disappeared on treatment with D2O, 1H). IR:  1603, 3303 cm-1. Anal. (C28H24N2O6S (516.56)) C, H, 
N, S.  
(2-(Furan-2-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (21).  Synthesized as 9, 
starting from 111.19 Yield 5%, mp 115-117 °C (from ethanol). 1H NMR (CDCl3):  3.80 (s, 6H), 3.95 
(s, 3H), 6.50-6.51 (m, 1H), 7.10-7.15 (m, 3H), 7.22-7.26 (m, 2H), 7.41-7.46 (m, 2H), 7.52-7.53 (m, 
1H), 9.11 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  1643, 3358 cm-1. Anal. 
(C22H19NO5 (377.99)) C, H, N.  
 (2-(Furan-3-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (23). Synthesized as 9, 
starting from 112.19 Yield 32%, mp 115-117 °C (from ethanol). 1H NMR (CDCl3):  3.78 (s, 6H), 3.93 
(s, 3H), 6.60-6.61 (m, 1H), 7.13 (s, 2H), 7.15-7.19 (m, 1H), 7.25-7.27 (m, 1H), 7.43-7.46 (m, 2H), 
7.58-7.60 (m, 1H), 8.05-8.06 (m, 1H), 8.70 ppm (broad s, disappeared on treatment with D2O, 1H). IR: 
 1598, 3345 cm-1. Anal. (C22H19NO5 (377.99)) C, H, N. 
 (2-(Thiophen-3-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (25). Synthesized as 9, 
starting from 113.19 Yield 25%, mp 118-120 °C (from ethanol). 1H NMR (CDCl3):  3.74 (s, 6H), 3.87 
(s, 3H), 7.04 (s, 2H), 7.11-7.12 (m, 1H), 7.23-7.28 (m, 2H), 7.29-7.33 (m, 1H), 7.44-7.47 (m, 1H), 
7.50-7.51 (m, 1H), 7.91-7.93 (m, 1H), 8.60 ppm (broad s, disappeared on treatment with D2O, 1H). IR: 
 1606, 3337 cm-1. Anal. (C22H19NO4S (393.46)) C, H, N, S. 
 (2-(Oxazol-2-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (32). Synthesized as 9, 
starting from 114. Yield 28%, mp 208-210 °C (from ethanol). 1H NMR (CDCl3):  3.79 (s, 6H), 3.94 
(s, 3H), 7.20-7.26 (m, 4H), 7.35-7.39 (m, 1H), 7.49-7.56 (m, 2H), 7.73-7.75 (m, 1H), 9.69 ppm (broad 
s, disappeared on treatment with D2O, 1H). IR:  1608, 3137 cm-1. Anal. (C21H18N2O5 (378.38)) C, H, 
N. 
(2-Phenyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (35). Synthesized as 9, starting 
from 84. Yield 95%, mp 207-212 °C (from ethanol). 1H NMR (DMSO-d6):  3.59 (s, 3H), 3.60 (s, 6H), 
6.82 (s, 2H), 7.18-7.28 (m, 5H), 7.36-7.38 (m, 2H), 7.50-7.53 (m, 1H), 7.92-7.94 (m, 1H), 12.20 ppm 
(broad s, disappeared on treatment with D2O, 1H). IR:  1590, 3213 cm-1. Anal. (C24H21NO4 (387.43)) 
C, H, N. 
 (2-(2-Fluorophenyl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (40). Synthesized as 9, 
starting from 86. Yield 65%, mp 180-185 °C (from toluene). 1H NMR (DMSO-d6):  3.59 (s, 3H), 3.64 
(s, 6H), 6.79 (s, 2H), 7.07-7.35 (m, 5H), 7.45-7.48 (m, 1H), 7.52 (d, J = 8.0 Hz, 1H), 7.95 (d, J = 7.8 
Hz, 1H), 12.27 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  1591, 3187 cm-1. Anal. 
(C24H20FNO4 (405.42)) C, H, N, F. 
 (2-(3-Fluorophenyl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (42). Synthesized as 9, 
starting from 87. Yield 52%, mp 190-195 °C (from toluene). 1H NMR (DMSO-d6):  3.60 (s, 3H), 3.62 
(s, 6H), 6.78 (s, 2H), 7.11 (t, J = 8.8 Hz, 2H), 7.20 (t, J = 7.6 Hz, 1H), 7.27 (t, J = 7.2 Hz, 1H), 7.39-
7.42 (m, 2H), 7.51 (d, J = 7.9 Hz, 1H), 7.94 (d, J = 7.8 Hz, 1H), 12.21 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR:  1594, 3221 cm-1. Anal. (C24H20FNO4 (405.42)) C, H, F, N. 
 (2-(4-Fluorophenyl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (44). Synthesized as 9, 
starting from 88. Yield 64%, mp 210-215 °C (from toluene). 1H NMR (DMSO-d6):  3.60 (s, 3H), 3.62 
(s, 6H), 6.78 (s, 2H), 7.10 (t, J = 8.9 Hz, 2H), 7.20 (t, J = 7.3 Hz, 1H), 7.27 (t, J = 7.1 Hz, 2H), 7.38-
7.42 (m, 2H), 7.51 (d, J = 8.2 Hz, 1H), 12.22 ppm (broad s, disappeared on treatment with D2O, 1H). 
IR:  1592, 3218 cm-1. Anal. (C24H20FNO4 (405.42)) C, H, F, N. 
 (2-(4-Methoxyphenyl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (51). Synthesized as 
9, starting from 91. Yield 9%, mp 170-175 °C (from ethanol). 1H NMR (CDCl3):  3.72 (s, 6H), 3.78 
(s, 3H), 3.84 (s, 3H), 6.76-6.79 (m, 2H), 7.00 (s, 2H), 7.27-7.34 (m, 4H), 7.46-7.48 (m, 1H), 8.03-8.05 
(m, 1H), 8.70 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  1614, 3144 cm-1. Anal. 
(C25H23NO5 (417.45)) C, H, N. 
(2-(Naphthalen-2-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (63). Synthesized as 9, 
starting from 103. Yield 33%, mp 182-186 °C (from ethanol). 1H NMR (CDCl3):  3.56 (s, 3H), 3.63 
(s, 6H), 6.98 (s, 2H), 7.29-7.37 (m, 2H), 7.43 (dd, J = 1.8 and 8.5 Hz, 1H), 7.47-7.52 (m, 3H), 7.68-
7.78 (m, 3H), 7.87 (m, 1H), 8.10-8.11 (m, 1H), 8.80 ppm (broad s, disappeared on treatment with D2O, 
1H). IR:  1609, 3170 cm-1. Anal. (C28H23NO4 (437.49)) C, H, N. 
 (2-Cyclobutyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (74). Synthesized as 9, 
starting from 94. Yield 75%, mp 60-63 °C (from ethanol). 1H NMR (DMSO-d6):  1.84-1.94 (m, 2H), 
2.14-2.22 (m, 2H), 2.29-2.39 (m, 2H), 3.76 (s, 6H), 3.77 (s, 3H), 3.79-3.81 (m, 1H), 6.94 (s, 2H), 7.02-
7.06 (m, 1H), 7.12-7.16 (m, 1H), 7.40-7.42 (m, 1H), 7.44-7.47 (m, 1H), 11.95 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR:  1600, 3217 cm-1. Anal. (C22H23NO4 (365.42)) C, H, N. 
 (2-Cyclopentyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (76). Synthesized as 9, 
starting from 95. Yield 68%, mp 110-115 °C (from ethanol). 1H NMR (DMSO-d6):  1.57-1.62 (m, 
2H), 1.75-1.85 (m, 4H), 1.95-1.99 (m, 2H), 3.37-3.45 (m, 1H), 3.76 (s, 6H), 3.78 (s, 3H), 6.97 (s, 2H), 
7.0-7.04 (m, 1H), 7.10-7.14 (m, 1H), 7.29-7.31 (m, 1H), 7.41-7.43 (m, 1H), 11.77 ppm (broad s, 
disappeared on treatment with D2O, 1H). IR:  1603, 3261 cm-1. Anal. (C23H25NO4 (379.45)) C, H, N. 
 (2-Cyclohexyl-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (78). Synthesized as 9, 
starting from 96. Yield 68%, mp 140-145 °C (from ethanol). 1H NMR (DMSO-d6):  1.08-1.26 (m, 
3H), 1.59-1.70 (m, 3H), 1.77-1.83 (m, 4H), 2.89-2.95 (m, 1H), 3.75 (s, 6H), 3.76 (s, 3H), 6.95 (s, 2H), 
7.01-7.05 (m, 1H), 7.10-7.14 (m, 1H), 7.38-7.42 (m, 2H), 11.80 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR:  1602, 3285 cm-1. Anal. (C24H27NO4 (393.48)) C, H, N. 
 ((2-(1H-Pyrrol-3-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (8). A mixture of 9 (0.1 
g, 0.00019 mol) and 2 M NaOH (0.6 mL) in methanol (2 mL) was heated at reflux for 3 h. After 
cooling, the reaction mixture was made acidic with 2 M HCl (pH ≈ 3-4) and extracted with ethyl 
acetate. The organic layer was washed with brine, dried and filtered. Removal of the solvent gave a 
residue that was purified by column chromatography (silica gel, ethyl acetate:n-hexane = 1:1 as eluent) 
to furnish 8 (0.7 g, 98%), mp 114-115 °C (from ethanol). 1H NMR (CDCl3):  3.77 (s, 6H), 3.90 (s, 
3H), 6.42-6.44 (m, 1H), 6.77-6.79 (m, 1H), 7.10 (s, 2H), 7.14-7.25 (m, 3H), 7.40-7.42 (m, 1H), 7.67-
7.71 (m, 1H), 8.38 (broad s, disappeared on treatment with D2O, 1H), 8.53 ppm (broad s, disappeared 
on treatment with D2O, 1H). IR:  1614, 3241, 3333 cm-1. Anal. (C22H20N2O4 (376.41)) C, H, N. 
 (2-(4,5-Dihydrooxazol-2-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone (29). 
Synthesized as 28, starting from 3-(3,4,5-trimethoxybenzoyl)-1H-indole-2-carboxylic acid. Yield 47%, 
mp 220-225 °C (from ethanol). 1H NMR (CDCl3):  3.84 (s, 6H), 3.94 (s, 3H), 3.99 (m, 2H), 4.19 (m, 
2H), 7.19 (s, 2H), 7.21-7.23 (m, 1H), 7.34-7.37 (m, 1H), 7.45-7.47 (m, 1H), 7.70-7.72 (m, 1H), 10.24 
ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3182 cm-1. Anal. (C21H20N2O5 (380.39)) 
C, H, N. 
3-(3,4,5-Trimethoxybenzoyl)-1H-indole-2-carboxylic acid. A mixture of methyl 3-(3,4,5-
trimethoxybenzoyl)-1H-indole-2-carboxylate18 (0.42 g, 0.00065 mol) and 3 N NaOH (2 mL) was 
placed into the microwave cavity (closed vessel mode, Pmax = 250 PSI). A starting microwave 
irradiation of 150 W was used, the temperature being ramped from 25 to 110 °C, while stirring. Once 
110 °C was reached, taking about 1 min, the reaction mixture was held at this temperature for 2 min, 
then made acidic with 3 N HCl (pH ≈ 3-4) and extracted with ethyl acetate. The organic layer was 
washed with brine, dried, filtered and evaporated to give 3-(3,4,5-trimethoxybenzoyl)-1H-indole-2-
carboxylic acid (0.23 g, 98%). 1H NMR (CDCl3):  3.84 (s, 6H), 1.09 (s, 3H), 7.11 (s, 2H), 7.16-7.20 
(m, 1H), 7.23-7.25 (m, 1H), 7.39-7.43 (m, 1H), 7.67 (m, 1H), 10.88 (broad s, disappeared on treatment 
with D2O, 1H), 12.95 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  1696, 2837, 2933, 
3265 cm-1. Anal. (C19H17NO6 (355.34)) C, H, N.  
 
Arylmethyl-1H-indoles. General Procedure for the Preparation of Compounds 12, 22, 24, 26, 
36, 52, 61 and 65. Example. 2-(1-(Phenylsulfonyl)-1H-pyrrol-3-yl)-3-(3,4,5-trimethoxybenzyl)-1H-
indole (12). Borane tetrahydrofuran complex 1 M solution in THF (0.85 mL, 0.00085 mol) was added 
to an ice-cooled solution of 9 (0.1 g, 0.019 mol) in acetonitrile (1.2 mL) containing methanol (0.017 
mL) under an Ar stream. The reaction mixture was heated at 50 °C for 1 h. After cooling, the reaction 
mixture was quenched on crushed ice and extracted with ethyl acetate. The organic layer was washed 
with brine, dried and filtered. Removal of the solvent gave a residue that was purified by column 
chromatography (silica gel, ethyl acetate:n-hexane = 1:1 as eluent) to furnish 12 (0.08 g, 84%), mp 
176-180 °C (from ethanol). 1H NMR (DMSO-d6): 3.55 (s, 6H), 3.59 (s, 3H), 4.15 (s, 2H), 6.46 (s, 
2H), 6.81-6.82 (m, 1H), 6.97-6.99 (m, 1H), 7.06-7.08 (m, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.48-7.50 (m, 
2H), 7.62-7.66 (m, 3H), 7.75-7.76 (m, 1H), 7.94-7.96 (m, 2H), 11.16 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR:  3293 cm-1. Anal. (C28H26N2O5S (502.58)) C, H, N, S. 
2-(Furan-2-yl)-3-(3,4,5-trimethoxybenzyl)-1H-indole (22). Synthesized as 12, starting from 21. 
Yield 9%, mp 78-80 °C (from ethanol). 1H NMR (CDCl3):  3.76 (s, 6H), 3.82 (s, 3H), 4.30 (s, 2H), 
6.51-6.55 (m, 4H), 7.09-7.13 (m, 1H), 7.21-7.24 (m, 1H), 7.40-7.43 (m, 1H), 7.52-7.54 (m, 2H), 8.49 
ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3347 cm-1. Anal. (C22H21NO4 (363.41)) 
C, H, N. 
2-(Furan-3-yl)-3-(3,4,5-trimethoxybenzyl)-1H-indole (24). Synthesized as 12, starting from 23. 
Yield 13%, mp 102-105 °C (from ethanol). 1H NMR (CDCl3):  3.73 (s, 6H), 3.80 (s, 3H), 4.18 (s, 2H), 
6.44 (s, 2H), 6.65-6.66 (m, 1H), 7.07-7.11 (m, 1H), 7.17-7.19 (m, 1H), 7.37-7.39 (m, 1H), 7.47-7.49 
(m, 1H), 7.52-7.53 (m, 1H), 7.63-7.64 (m, 1H), 8.07 ppm (broad s, disappeared on treatment with D2O, 
1H). IR:  3320 cm-1. Anal. (C22H21NO4 (363.41)) C, H, N. 
2-(Thiophen-3-yl)-3-(3,4,5-trimethoxybenzyl)-1H-indole (26). Synthesized as 12, starting from 
25. Yield 61%, mp 165-168 °C (from ethanol). 1H NMR (CDCl3):  3.74 (s, 6H), 3.83 (s, 3H), 4.25 (s, 
2H), 6.48 (s, 2H), 7.10-7.14 (m, 1H), 7.21-7.25 (m, 1H), 7.34-7.35 (m, 1H), 7.40-7.46 (m, 3H), 7.51-
7.53 (m, 1H), 8.22 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3353 cm-1. Anal. 
(C22H21NO3S (379.47)) C, H, N, S. 
2-Phenyl-3-(3,4,5-trimethoxybenzyl)-1H-indole (36). Synthesized as 12, starting from 35. Yield 
26%, mp 187-192 °C (from ethanol). 1H NMR (DMSO-d6):  3.59 (s, 3H), 3.60 (s, 6H), 4.17 (s, 2H), 
6.46 (s, 2H), 6.97-7.01 (m, 1H), 7.09-7.13 (m, 1H), 7.37-7.41 (m, 2H), 7.47-7.53 (m, 3H), 7.64-7.66 
(m, 2H), 11.28 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3351 cm-1. Anal. 
(C24H23NO3 (373.44)) C, H, N. 
2-(4-Methoxyphenyl)-3-(3,4,5-trimethoxybenzyl)-1H-indole (52). Synthesized as 12, starting 
from 51. Yield 4% as an oil. 1H NMR (CDCl3):  3.73 (s, 6H), 3.82 (s, 3H), 3.86 (s, 3H), 4.19 (s, 2H), 
6.46 (s, 2H), 6.98-7.00 (m, 2H), 7.07-7.11 (m, 1H), 7.18-7.22 (m, 1H), 7.39-7.41 (m, 1H), 7.46-7.49 
(m, 3H), 8.09 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3356 cm-1. Anal. 
(C25H25NO4 (403.47)) C, H, N. 
2-(Naphthalen-1-yl)-3-(3,4,5-trimethoxybenzyl)-1H-indole (61). Synthesized as 12, starting from 
60. Yield 99%, mp 142-147 °C (from ethanol). 1H NMR (CDCl3):  3.60 (s, 6H), 3.74 (s, 3H), 4.03 (s, 
2H), 6.26 (s, 2H), 7.18-7.20 (m, 1H), 7.25-7.29 (m, 1H), 7.43-7.47 (m, 2H), 7.52-7.58 (m, 3H), 7.63-
7.65 (m, 1H), 7.84-7.86 (m, 1H), 7.94-7.96 (m, 2H), 8.19 ppm (broad s, disappeared on treatment with 
D2O, 1H). IR:  3317 cm-1. Anal. (C28H25NO3 (423.50)) C, H, N. 
2-(Naphthalen-2-yl)-3-(3,4,5-trimethoxybenzyl)-1H-indole (65). Synthesized as 12, starting from 
63. Yield 73%, mp 138-140 °C (from ethanol). 1H NMR (CDCl3):  3.73 (s, 6H), 3.83 (s, 3H), 4.29 (s, 
2H), 6.52 (s, 2H), 7.13-7.17 (m, 1H), 7.24-7.28 (m, 1H), 7.46 (d, J = 8.1 Hz, 1H), 7.51-7.58 (m, 3H), 
7.70 (dd, J = 1.8 and 8.5 Hz, 1H), 7.82-7.94 (m, 3H), 7.99 (m, 1H), 8.30 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR:  3359 cm-1. Anal. (C28H25NO3 (423.50)) C, H, N. 
2-(1H-Pyrrol-3-yl)-3-(3,4,5-trimethoxybenzyl)-1H-indole (13). Synthesized as 8, from 12. Yield 
20%, mp 195-197 °C (from ethanol). 1H NMR (DMSO-d6):  3.59 (s, 3H), 3.61 (s, 6H), 4.14 (s, 2H), 
6.48-6.49 (m, 1H), 6.53 (s, 2H), 6.86-6.92 (m, 2H), 6.97-7.01 (m, 1H), 7.12-7.13 (m, 1H), 7.29 (d, J = 
7.8 Hz, 1H), 7.37 (d, J = 7.7 Hz, 1H), 10.88 (broad s, disappeared on treatment with D2O, 1H), 11.03 
ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3242 cm-1. Anal. (C22H22N2O3 (362.42)) 
C, H, N. 
2-(3-(3,4,5-Trimethoxybenzyl)-1H-indol-2-yl)-4,5-dihydroxazole (30). Synthesized as 28, starting 
from 3-(3,4,5-trimethoxybenzyl)-1H-indole-2-carboxylic acid. Yield 80%, mp 160-165 °C (from 
ethanol). 1H NMR (CDCl3):  3.77 (s, 6H), 3.80 (s, 3H), 4.09 (t, J = 9.5 Hz, 2H), 4.44-4.52 (m, 4H), 
6.55 (s, 2H), 7.07-7.11 (m, 1H), 7.25-7.29 (m, 1H), 7.36 (dd, J = 0.75 and 8.3 Hz, 1H), 7.56 (d, J = 8.2 
Hz, 1H), 9.10 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3257 cm-1. Anal. 
(C21H22N2O4 (366.41)) C, H, N. 
3-(3,4,5-Trimethoxybenzyl)-1H-indole-2-carboxylic acid. Was obtained from methyl 3-(3,4,5-
trimethoxybenzyl)-1H-indole-2-carboxylate.18 Yield 96%, mp 240-245 °C (from ethanol). 1H NMR 
(DMSO-d6):  3.56 (s, 3H), 3.66 (s, 6H), 4.37 (s, 2H), 6.65 (s, 2H), 6.99-7.03 (m, 1H), 7.18-7.23 (m, 
1H), 7.38 (d, J = 8.0 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H), 11.48 (broad s, disappeared on treatment with 
D2O, 1H), 13.05 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  1663, 2840, 3354 cm-1. 
Anal. (C19H19NO5 (341.36)) C, H, N. 
 
Arylmethanol-1H-indoles. (2-(1H-Pyrrol-3-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)metha 
nol (10). Synthesized as 8, starting from 11. Yield 98%, mp 189-191 °C (from ethanol). 1H NMR 
(CDCl3):  3.57 (s, 6H), 3.86 (s, 3H), 5.13 (m, 1H), 6.00 (s, disappeared on treatment with D2O, 1H), 
6.38-6.39 (m, 2H), 6.54 (s, 1H), 6.62-6.64 (m, 1H), 6.75-6.78 (m, 3H), 6.85-6.88 (m, 1H), 7.00-7.03 
(m, 1H), 8.01 (broad s, disappeared on treatment with D2O, 1H), 8.16 ppm (broad s, disappeared on 
treatment with D2O, 1H). IR:  2852, 2922, 3382 cm-1. Anal. (C22H22N2O4 (378.42)) C, H, N. 
General Procedure for the Preparation of Compounds 11 and 64. Example. (2-(1-
(Phenylsulfonyl)-1H-pyrrol-3-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanol (11). To a 
solution of 9 (0.5 g, 0.0013 mol) in THF (2.6 mL) containing 0.08 mL of water was carefully added 
sodium borohydride (0.049 g, 0.0013 mol). The reaction mixture was heated at 80 °C for 2 h. After 
cooling, the mixture was diluted with water and extracted with ethyl acetate. The organic layer was 
washed with brine, dried and filtered. Removal of the solvent gave a residue that was purified by 
column chromatography (silica gel, acetone:n-hexane = 1:1 as eluent) to furnish 11 (0.54 g, 97%), mp 
90-94 °C (from ethanol). 1H NMR (DMSO-d6): 3.58 (s, 6H), 3.60 (s, 3H), 5.71-5.73 (m, 1H), 6.05 (s, 
disappeared on treatment with D2O, 1H), 6.63 (s, 2H), 6.83-6.86 (m, 2H), 7.01 (t, J = 6.6 Hz, 1H), 7.27 
(d, J = 8.4 Hz, 1H), 7.36 (d, J = 7.4 Hz, 1H), 7.47-7.50 (m, 1H), 7.63-7.67 (m, 2H), 7.74-7.77 (m, 2H), 
7.98 (d, J = 7.1 Hz, 2H), 11.14 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  2938, 
3341 cm-1. Anal. (C28H26N2O6S (518.58)) C, H, N, S. 
 (2-(Naphthalen-2-yl)-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanol (64). Synthesized as 11, 
starting from 63. Yield 44%, mp 145-150 °C (from ethanol). 1H NMR (CDCl3):  2.29 (d, J = 4.2 Hz, 
1H), 3.76 (s, 6H), 3.84 (s, 3H), 6.29 (d, J = 4.2 Hz, 1H), 6.79 (s, 2H), 7.07-7.11 (m, 1H), 7.22-7.26 (m, 
1H), 7.43-7.46 (m, 1H), 7.55-7.60 (m, 3H), 7.72 (dd, J = 1.8 and 8.5 Hz, 1H), 7.87-7.91 (m, 2H), 7.96 
(d, J = 8.4 Hz, 1H), 8.06 (m, 1H), 8.35 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  
3286, 3295, 3293 cm-1. Anal. (C28H25NO4 (439.50)) C, H, N. 
 
Synthetic intermediates. 2-(1H-Imidazol-2-yl)-1H-indole (79).  (Diacetoxyiodo)benzene (0.52 g, 
0.0016 mol) was added to a mixture of 2-(4,5-dihydro-1H-imidazol-2-yl)-1H-indole (83) (0.27 g, 
0.0015 mol) and potassium carbonate (0.22 g, 0.0016 mol) in DMSO (15 mL). The reaction mixture 
was stirred at 25 °C for 12 h under an Ar stream, then diluted with a saturated aqueous solution of 
sodium hydrogen carbonate and extracted with ethyl acetate. The organic layer was washed with brine, 
dried and filtered. Removal of the solvent gave a residue that was purified by column chromatography 
(silica gel, ethyl acetate:n-hexane = 1:1 as eluent) to furnish 79 (0.08 g, 29%), mp 130-133 °C (from 
ethanol). 1H NMR (DMSO-d6):  7.12 (t, J = 7.5 Hz, 1H), 7.20 (t, J = 7.4 Hz, 1H), 7.23-7.25 (m, 3H), 
7.32 (d, J = 7.8 Hz, 1H), 7.41 (d, J = 7.8 Hz, 1H), 11.90 (broad s, disappeared on treatment with D2O, 
1H), 12.19 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  2920, 3060, 3120, 3380 cm-1. 
2-(1H-1,2,4-Triazol-1-yl)-1H-indole (81). A mixture of 2-iodo-1H-indole23 (106) (0.5 g, 0.0021 
mol) and triazole (0.14 g, 0.021 mol) was heated at 150 °C for 2 h. After cooling, the mixture was 
purified by column chromatography (silica gel, ethyl acetate as eluent) to give 81 (0.16 g, 42%) as a 
powder. 1H NMR (DMSO-d6):  6.76 (s, 1H), 7.08 (t, J = 7.2 Hz, 1H), 7.17 (t, J = 7.1 Hz, 1H), 7.43 (d, 
J = 8.3 Hz, 1H), 7.58 (d, J = 7.9 Hz, 1H), 8.32 (s, 1H), 9.22 (broad s, disappeared on treatment with 
D2O, 1H), 12.19 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3112 cm-1. 
2-(1H-Indol-2-yl)thiazole (82). A mixture 2-bromo-1-(thiazol-2-yl)ethanone (122) (0.5 g, 0.0024 
mol) and aniline (0.67 g, 0.6 mL, 0.0072 mol) in anhydrous DMF (2 mL) was placed into the 
microwave cavity (closed vessel mode, Pmax = 250 PSI). A starting microwave irradiation of 100 W 
was used, the temperature being ramped from 25 to 150 °C, while stirring. Once 150 °C was reached, 
taking about 1 min, the reaction mixture was held at this temperature for 1 min, while cooling, then 
diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, dried and 
filtered. Removal of the solvent gave a residue that was purified by column chromatography (silica gel, 
ethyl acetate:n-hexane = 2:7 as eluent) to furnish 82 (0.25 g, 52%), mp 112-115 °C (from ethanol). 
2-(4,5-Dihydro-1H-imidazol-2-yl)-1H-indole (83). Ethylenediamine (0.23 g, 0.25 mL, 0.0038 mol) 
was added to a solution of 1H-indole-2-carbaldehyde26 (115) (0.5 g, 0.0034 mol) in tert-tutanol (34 
mL). The reaction mixture was stirred at 25 °C for 30 min under an Ar stream. Iodine (1.08 g, 0.00425 
mol) and potassium carbonate (1.41 g, 0.01 mol) were added, and the reaction mixture was heated at 70 
°C for 3 h. After cooling, the mixture was diluted with a saturated aqueous solution of sodium sulfite 
and extracted with chloroform. The organic layer was washed with brine, dried and filtered. Removal 
of the solvent gave a residue that was purified by column chromatography (silica gel,  
chloroform:ethanol = 8:2 as eluent) to furnish 83 (0.27 g, 43%). 1H NMR (D MSO-d6):  3.70 (s, 4H), 
7.13 (t, J = 7.6 Hz, 1H), 7.25 (t, J = 6.9 Hz, 1H), 7.35 (d, J = 7.8 Hz, 1H), 7.42 (d, J = 8.2 Hz, 1H), 
8.68 (broad s, disappeared on treatment with D2O, 1H), 11.79 ppm (broad s, disappeared on treatment 
with D2O, 1H). IR:  3387, 2855 cm-1. 
General Procedure for the Preparation of Compounds 85, 91-94 and 103. Example. 2-(4-
Chlorophenyl)-1H-indole (85). 1-(1-(4-Chlorophenyl)ethylidene)-2-phenylhydrazine (128) (2.82 g, 
0.011 mol) was added in portions to polyphosphoric acid (28 g) at 120 °C. The reaction mixture was 
stirred at the same temperature for 1 h. After cooling, it was quenched on crushed ice and treated with 3 
N NaOH with stirring, then extracted with ethyl acetate. The organic layer was washed with brine, 
dried and filtered. Removal of the solvent gave a residue that was purified by column chromatography 
(silica gel, ethyl acetate:n-hexane = 1:1 as eluent) to furnish 85 (2.1 g, 80%), mp 210-212 °C (from 
ethanol). Lit.37 mp 206.3-209.0 °C. 
2-(4-Methoxyphenyl)-1H-indole (91). Synthesized as 85, starting from 1-(1-(4-
methoxyphenyl)ethylidene)-2-phenylhydrazine (129). Yield 37%, mp 222-224 °C (from toluene). Lit.38 
mp 224-227 °C.  
2-(Pyridin-2-yl)-1H-indole (92). Synthesized as 85, starting from 2-(1-(2-
phenylhydrazono)ethyl)pyridine29 (130). Yield 73%, mp 154-156 °C (from ethanol). Lit.39 mp 156.0-
156.5 °C.  
2-(Pyridin-3-yl)-1H-indole (93). Synthesized as 85, starting from 3-(1-(2-
phenylhydrazono)ethyl)pyridine29 (131). Yield 73%, mp 168-170 °C (from ethanol). Lit.40 mp 169-170 
°C. 
2-(Pyridin-4-yl)-1H-indole (94). Synthesized as 85, starting from 4-(1-(2-
phenylhydrazono)ethyl)pyridine29 (132). Yield 68%, mp 237-239 °C (from ethanol). Lit.41 mp 238-239 
°C. 
2-(Naphthalen-2-yl)-1H-indole (103). Synthesized as 85, starting from 1-(1-(naphthalen-2-
yl)ethylidene)-2-phenylhydrazine29 (133). Yield 45%, mp 165-168 °C (petroleum ether). Lit.42 mp 
163-165 °C. 
General Procedure for the Preparation of Compounds 86-90, 101 and 102. Example. 2-(2-
fluorophenyl)-1H-indole (86). A solution of bromo-1-(2-fluorophenyl)ethanone (116) (0.9 g, 0.0041) 
in N,N-dimethylaniline (1.8 mL) was added dropwise to aniline (1.26 g, 1.2 mL, 0.0135 mol) in the 
same solvent (2.4 mL). The reaction mixture was heated at 170 °C for 15 min. After cooling to 0 °C, 
the mixture was made acidic with 1 M HCl (pH ≈ 3-4) and extracted with ethyl acetate. The organic 
layer was washed with brine, dried and filtered. Removal of the solvent gave a residue that was purified 
by column chromatography (silica gel, acetone:n-hexane = 1:3 as eluent) to furnish 89 (0.3 g, 35%), 
mp 102-104 °C (from toluene), 1H NMR (DMSO-d6):  6.92 (s, 1H), 7.03 (t, J = 7.8 Hz, 1H), 7.14 (t, J 
= 7.8 Hz, 1H), 7.34-7.40 (m, 3H), 7.45 (d, J = 8.0 Hz, 1H), 7.58 (d, J = 7.9 Hz, 1H), 7.93 (t, J = 7.6 Hz, 
1H), 11.48 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3412 cm-1. Lit.43 mp 97-98.5 
°C. 
2-(3-Fluorophenyl)-1H-indole (87). Synthesized as 86, starting from 2-bromo-1-(3-
fluorophenyl)ethanone (117). Yield 42%, mp 142-144 °C (from toluene). Lit.44 mp 144 °C. 
2-(4-Fluorophenyl)-1H-indole (88). Synthesized as 86, starting from 2-bromo-1-(4-
fluorophenyl)ethanone (118). Yield 42%, mp 182-187 °C (from toluene). Lit.44 mp 185 °C. 
2-(2-Methoxyphenyl)-1H-indole (89). Synthesized as 86, starting from 2-bromo-1-(2-
methoxyphenyl)ethanone28 (119). Yield 41%, mp 75-80 °C (from toluene). Lit.45 mp 78.5-81.0 °C.  
2-(3-Methoxyphenyl)-1H-indole (90). Synthesized as 86, starting from 2-bromo-1-(3-
methoxyphenyl)ethanone28 (120). Yield 40%, mp 138-141 °C (from toluene). Lit.37 mp 139.4-140.7 
°C. 
2-(3-Isopropoxy-4-methoxyphenyl)-1H-indole (101). Synthesized as 86, starting from 2-bromo-1-
(4-fluorophenyl)ethanone (121). Yield 12%, mp 137-141 °C (from ethanol). 1H NMR (CDCl3):  1.42 
(s, 3H), 1.43 (s, 3H), 3.90 (s, 3H), 4.64 (m, 1H), 6.72 (s, 1H), 6.95 (d, J = 8.2 Hz, 1H), 7.10-7.27 (m, 
5H), 7.39 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 8.0 Hz, 1H),  8.3 ppm (broad s, disappeared on treatment 
with D2O, 1H). IR:  3366 cm-1. 
2-(Naphthalen-1-yl)-1H-indole (102). Synthesized as 86, starting from 2-bromo-1-(naphthalen-1-
yl)ethanone (122). Yield 28%, mp 95-97 °C (from petroleum ether). Lit.46 mp 97-99 °C.  
General Procedure for the Preparation of Compounds 95-97, 100 and 104. Example. 2-(p-
Tolyl)-1H-indole (100). n-Butyl lithium (4.2 mL, 0.0067 mol; 1.6 M in n-hexane) was added dropwise 
to a –40 °C solution of 4-methyl-N-(o-tolyl)benzamide (123) (0.5 g, 0.0022 mol) in anhydrous THF (18 
mL). After stirring at –40 °C for 1 h, the reaction mixture was warmed at 0 °C for 1 h and then kept at 
25 °C for 12 h. The mixture was diluted with water and extracted with ethyl acetate. The organic layer 
was washed with brine, dried and filtered. Removal of the solvent gave a residue that was purified by 
column chromatography (silica gel, ethyl acetate:n-hexane = 1:5 as eluent) to furnish 100 (0.2 g, 43%), 
mp 217-219 °C (from ethanol). Lit.45 mp 218.0-219.9 °C. 
2-((1,1'-Biphenyl)-4-yl)-1H-indole (104). Synthesized as 100, starting from N-(o-tolyl)-(1,1'-
biphenyl)-4-carboxamide (124). Yield 22%, mp 296-298 °C (from ethanol),. 1H NMR (DMSO-d6):  
6.97-7.04 (m, 2H), 7.10-7.14 (t, J = 8.0 Hz, 1H), 7.37-7.41 (m, 2H) 7.44-7.56 (m, 3H), 7.75-7.80 (m, 
4H), 7.97 (d, J = 8.0 Hz, 2H) 11,61 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  3681 
cm-1. Lit.47 mp 297-298 °C 
2-Cyclobutyl-1H-indole (95). Synthesized as 100, starting from N-(o-tolyl) 
cyclobutanecarboxamide (125). Yield 40%, mp 73-76 °C (from toluene). 1H NMR (DMSO-d6):  1.86-
2.03 (m, 2H), 2.19-2.33 (m, 2H), 2.58-2.54 (m, 2H), 3.57-3.66 (m, 1H), 6.16-6.17 (m, 1H), 6.89-6.93 
(m, 1H), 6.98-7.01 (m, 1H), 7.26-7.29 (m, 1H), 7.39-7.41 (m, 1H), 10.90 (broad s, disappeared on 
treatment with D2O, 1H). IR:  3334 cm-1. 
2-Cyclopentyl-1H-indole (96). Synthesized as 100, starting from N-(o-tolyl) 
cyclopentanecarboxamide (126). Yield 40%, mp 80-82 °C (from toluene). Lit.48 mp 84-85 °C. 
2-Cyclohexyl-1H-indole (97). Synthesized as 100, starting from N-(o-tolyl) 
cyclohexanecarboxamide (127). Yield 59%, mp 101-103 °C (from toluene). Lit.49 mp 103-105 °C. 
2-(1H-Pyrazol-4-yl)-1H-indole (98). A mixture of 106 (0.1 g, 0.00041 mol), 1-Boc-pyrazole-4-
boronic acid pinacol ester (0.18 g, 0.000615 mol) and 1 M potassium carbonate (4.1 mL) in DMF (2 
mL) was degassed for 30 min. PdCl2(PPh3)2 (0.003 g, 0. 0041 mmol) was added, and the reaction 
mixture was placed into the microwave cavity (closed vessel mode, Pmax = 250 PSI). A starting 
microwave irradiation of 250 W was used, the temperature being ramped from 25 °C to 160 °C, while 
stirring. Once 160 °C was reached, taking about 2 min, the reaction mixture was held at this 
temperature for 10 min. The reaction mixture was diluted with water, neutralized with 1 M HCl and 
extracted with ethyl acetate. The organic layer was washed with brine, dried and filtered. Removal of 
the solvent gave a residue that was purified by column chromatography (silica gel, diethyl 
ether:methanol:n-hexane = 8:1:2 as eluent) to furnish 79 (0.02 g, 26%), mp 220-225 °C (from ethanol). 
1H NMR (DMSO-d6):  6.55 (s, 1H), 6.97 (t, J = 7.6 Hz, 1H), 7.00 (t, J = 7.1 Hz, 1H), 7.32 (d, J = 7.9 
Hz, 1H), 7.44 (d, J = 7.7 Hz, 1H), 7.90-8.22 (m, 2H), 11.24 (broad s, disappeared on treatment with 
D2O, 1H), 13.05 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  2851, 2921, 3111, 3400 
cm-1.  
3-((3,4,5-Trimethoxyphenyl)thio)-1H-indole-2-carboxylic acid (107). Synthesized as 14, starting 
from 105. Yield 45%, mp 240-245 °C (from ethanol). 1H NMR (DMSO-d6):  3.33 (broad s, 
disappeared on treatment with D2O, 1H), 3.56 (s, 6H), 3.57 (s, 3H), 6.42 (s, 2H), 7.06-7.10 (m, 1H), 
7.26-7.30 (m, 1H), 7.40-7.42 (m, 1H), 7.47-7.49 (m, 1H), 12.18 (broad s, disappeared on treatment 
with D2O, 1H), 13.10 ppm (broad s, disappeared on treatment with D2O, 1H). IR:  1738, 2574, 3329 
cm-1.  
2-Iodo-3-((3,4,5-trimethoxyphenyl)thio)-1H-indole (108). Synthesized as 14, starting from 106. 
Yield 93%, mp 135-140 °C (from ethanol). 1H NMR (CDCl3):  3.71 (s, 6H), 3.79 (s, 6H), 6.68 (s, 2H), 
7.13-7.22 (m, 2H), 7.37-7.39 (m, 1H), 7.61-7.63 (m, 1H), 8.65 ppm (broad s, disappeared on treatment 
with D2O, 1H). IR:  3331 cm-1. 
2-(1H-Indol-2-yl)oxazole (114). Synthesized as 31, using 106 and 2-(tributylstannyl)oxazole.50 
Yield 26%, mp 33-35 °C (from toluene). 1H NMR (CDCl3):  7.16-7.20 (m, 2H), 7.27-7.32 (m, 2H), 
7.40-7.43 (m, 1H), 7.71 (d, J = 8.0 Hz, 1H), 7.77 (s, 1H), 8.65 (broad s, disappeared on treatment with 
D2O, 1H)10.05 ppm (broad s, disappeared on treatment with D2O, 1H),. IR:  3271 cm-1. 
General Procedure for the Preparation of Compounds 116-122. Example. 2-Bromo-1-(2-
fluorophenyl)ethanone (116). A solution of bromine (3.47 g, 1.1 mL, 0.0217 mol) in anhydrous 
dichloromethane (7 mL) was dropped into a solution of 1-(2-fluorophenyl)ethanone (3.0 g, 2.6 mL, 
0.00217 mol) in the same solvent (14 mL). The reaction mixture was stirred at 25 °C for 2 h, then 
diluted with a saturated aqueous solution of sodium hydrogen carbonate and extracted with 
dichloromethane. The organic layer was washed with brine, dried and filtered. Removal of the solvent 
gave a residue that was purified by column chromatography (silica gel, dichloromethane:petroleum 
ether = 7:3 as eluent) to furnish 116 as a slurry (0.9 g, 20%).51 
2-Bromo-1-(3-fluorophenyl)ethanone (117). Synthesized as 116, starting from 1-(3-
fluorophenyl)ethanone. Yield 21% as a slurry. 1H NMR (DMSO-d6):  (s, 2H), 7.53-7.65 (m, 2H), 
7.79-7.81 (m, 1H), 7.85-7.87 ppm (m, 1H). IR:  1686 cm-1. 
2-Bromo-1-(4-fluorophenyl)ethanone (118). Synthesized as 116, starting from 1-(4-
fluorophenyl)ethanone. Yield 73%, mp 47-49 °C (from n-hexane). 1H NMR (DMSO-d6):  (s, 
2H), 7.37-7.49 (m, 2H), 8.03-8.12 ppm (m, 2H). IR:  1694 cm-1. Lit.52 mp 48-49 °C. 
2-Bromo-1-(3-isopropoxy-4-methoxyphenyl)ethanone (121). A solution of 1-(3-hydroxy-4-
methoxyphenyl)ethanone (0.25 g, 0.0015 mol) in anhydrous DMF (5 mL) was added to mixture of 2-
iodopropane (0.28 g, 0.2 mL, 0.00165 mol) and potassium carbonate (0.415 g, 0.003 mol) in the same 
solvent (5 mL). The reaction was heated at 50 °C for 3 h. After cooling, the mixture was neutralized 
with 1 M HCl and extracted with ethyl acetate. The organic layer was washed with brine, dried and 
filtered. Removal of the solvent gave a residue that was purified by column chromatography (silica gel, 
ethyl acetate:n-hexane = 3:7 as eluent) to furnish 1-(3-isopropoxy-4-methoxyphenyl)ethanone (0.27 g, 
86%), mp 53-56 °C (from toluene/n-hexane). Lit53 mp 56 °C. As described above for 116, 1-(3-
isopropoxy-4-methoxyphenyl)ethanone was converted to 121, yield 65%, mp 75-80 °C (from ethanol). 
Bromo-1-(naphthalen-1-yl)ethanone (122). The compound was synthesized as 116, starting from 
1-(naphthalen-1-yl)ethanone. Yield 90%, mp 175-177 °C (petroleum ether), Lit.54 mp 177-179 °C. 
General Procedure for the Preparation of Compounds 123-127. Example. N-(o-Tolyl) 4-
methylbenzamide (123). To an ice-cooled solution of o-toluidine (5.0 g, 5 mL, 0.0047 mol) and 
triethylamine in anhydrous THF (160 mL) was added dropwise p-tolyl chloride (8.66 g, 7.4 mL, 0.056 
mol). The reaction was stirred at 25 °C for 12 h. The mixture was diluted with a saturated solution of 
sodium hydrogen carbonate and extracted with ethyl acetate. The organic layer was washed with brine, 
dried and filtered. Removal of the solvent gave a residue that was triturated with diethyl ether to furnish 
123 (8.05 g, 76%), mp 118-120 °C (from ethanol). Lit.55 mp 121 °C. 
N-(o-Tolyl)-(1,1'-biphenyl)-4-carboxamide (124). Synthesized as 123, starting from (1,1'-
biphenyl)-4-carbonyl chloride. Yield 40%, mp 176-178 °C (from ethanol), 1H NMR (CDCl3):  2.39 (s, 
3H), 7.14-7.18 (m, 1H), 7.27-7.33 (m, 2H), 7.42-7.44 (m, 1H), 7.45-7.54 (m, 2H), 7.65-7.68 (m, 2H), 
7.65-7.77 (m, 3H), 7.98-8.02 (m, 3H). IR:  1637-3280 cm-1. Lit.56 mp 179.5-180 °C. 
N-(o-Tolyl) cyclobutanecarboxamide (125). Synthesized as 123, starting from 
cyclobutanecarbonyl chloride. Yield 90%, mp 106-110 °C (from toluene). 1H NMR (CDCl3):  1.91-
2.07 (m, 2H), 2.23 (s, 3H), 2.26-2.44 (m, 4H), 3.16-3.24 (m, 1H), 6.86 (broad s, disappeared on 
treatment with D2O, 1H), 7.03-7.07 (m, 1H), 7.16-7.22 (m, 2H), 7.86 ppm (d, J = 7.8 Hz, 1H). IR:  
1646, 3256 cm-1. 
N-(o-Tolyl) cyclopentanecarboxamide (126). Synthesized as 123, starting from 
cyclopentanecarbonyl chloride. Yield 86%, mp 125-129 °C (from toluene). 1H NMR (DMSO-d6):  
1.52-1.88 (m, 8H), 2.18 (s, 3H), 2.81-2.88 (m, 1H), 7.05-7.08 (m, 1H), 7.13-7.16 (m, 1H), 7.19 (d, J = 
7.6 Hz, 1H), 7.33 (d, J = 7.6 Hz, 1H), 9.19 ppm (broad s, disappeared on treatment with D2O, 1H). IR: 
 1648, 3268 cm-1. 
N-(o-Tolyl) cyclohexanecarboxamide (127). Synthesized as 123, starting from 
cyclohexanecarbonyl chloride. Yield 85%, mp 150-155 °C (from toluene). 1H NMR (DMSO-d6):  
1.18-1.47 (m, 5H), 1.64-1.84 (m, 5H), 2.17 (s, 3H), 2.37-2.42 (m, 1H), 7.05-7.08 (m 1H), 7.12-7.16 (m, 
1H), 7.19 (d, J = 7.4 Hz, 1H), 7.32 (d, J = 7.1 Hz, 1H), 9.13 ppm (broad s, disappeared on treatment 
with D2O, 1H). IR:  1649, 3284 cm-1. 
 
General Procedure for the Preparation of Compounds 128 and 129. Example. 1-(1-(4-
Chlorophenyl)ethylidene)-2-phenylhydrazine (128). A mixture of phenylhydrazine hydrochloride 
(2.2 g, 0.015 mol), 4’-chloroacetophenone (1.054 g, 1.3 mL, 0.01 mol) and sodium acetate (1.23 g, 
0.015 mol) in ethanol (25 mL) was placed into the microwave cavity (open vessel mode). Microwave 
irradiation of 250 W was used, the temperature being ramped from 25 °C to 80 °C. Once 80 °C was 
reached, taking about 1 min, the reaction mixture was held at this temperature for 5 min with stirring. 
The reaction mixture was cooled to 0 °C, filtered, washed with petroleum ether and dried to give 128 
(3.38 g, 92%), mp 114-116 °C (from ethanol), 1H NMR (CDCl3):  2.23 (s, 3H), 6.91 (broad s, 
disappeared on treatment with D2O, 1H), 7.17-7.19 (m, 2H), 7.28-7.37 (m, 5H), 7.28-7.75 ppm (m, 
2H). IR:  3349 cm-1. Lit.57 mp 112-113 °C. 
1-(1-(4-Methoxyphenyl)ethylidene)-2-phenylhydrazine (129). Synthesized as 128, starting from 
4’-methoxyacetophenone (166). Yield 95%, mp 102-104 °C (from ethanol), 1H NMR (CDCl3):  2.23 
(s, 3H), 3.85 (s, 3H), 6.87 (broad s, disappeared on treatment with D2O, 1H), 6.90-6.94 (m, 2H), 7.17-
7.19 (m, 2H), 7.28-7.31 (m, 2H), 7.75-7.77 ppm (m, 2H). IR:  3336 cm-1. Lit.58 mp 97-98 °C. 
 
Biology. Tubulin Assembly. The reaction mixtures contained 0.8 M monosodium glutamate (pH 
6.6 with HCl in a 2 M stock solution), 10 μM tubulin, and varying concentrations of drug. Following a 
15 min preincubation at 30 °C, samples were chilled on ice, GTP to 0.4 mM was added, and turbidity 
development was followed at 350 nm in a temperature controlled recording spectrophotometer for 20 
min at 30 °C. Extent of reaction was measured. Full experimental details were previously reported.59 
[3H]Colchicine Binding Assay. The reaction mixtures contained 1.0 μM tubulin, 5.0 μM 
[3H]colchicine, and 5.0 μM inhibitor and were incubated 10 min at 37 °C. Complete details were 
described previously.60 
Cell Cultures and Treatment. Cell lines were obtained from the American Tissue Culture 
Collection (ATCC), unless specified otherwise. Cells were grown in Dulbecco’s Modified Eagle 
medium (D-MEM) supplemented with 10% fetal bovine serum (FBS) at 37 °C with 5% CO2. In all 
experiments 300,000 cells were plated in 9 cm2 dishes and exposed to test compound dissolved in 
DMSO (0.1% final concentration) at the indicated concentrations. 
HeLa, HT29, and A549 cell lines were grown at 37 °C in D-MEM containing 10 mM glucose 
supplemented with 10% FBS, 100 units/mL each of penicillin and streptomycin, and 2 mM glutamine. 
At the onset of each experiment, cells were placed in fresh medium and cultured in the presence of test 
compounds from 0.01 to 25 μM. 
231-MDA and A549 cells were cultured in DMEM supplemented with 10% FBS for 24, 48, and 72 
h in a 96-well tissue culture plate at 37 °C and 5% CO2 in the absence or presence of different drug 
concentrations. 
HCT 116, HCT 15, Messa and Messa/Dx5 were seeded into 96-well plates (Corning Inc., Costar) at 
a density of 2 x 103 cells/well in a volume of 50 μL of the appropriate tissue culture medium. 
Compounds were added with different concentrations for the indicated incubation time at 37 °C with 
5% CO2. 
The human glioblastoma multiforme (GBM) cell line U87MG was purchased from the National 
Institute for Cancer Research (ICLC) of Genoa (Italy). The U87MG cells (1x106) were seeded onto T-
75 flasks and cultured in RPMI medium supplemented with 10% FBS, 2 mM L-glutamine, 100 U/mL 
penicillin, 100 mg/mL streptomycin and 1% non-essential amino acids at 37 °C in humidified 
atmosphere composed by oxygen (95%) and carbon dioxide (5%). For U87MG cell treatments, the 
cells were seeded at appropriate densities (5,000 cells/well in 96-well plates or 50,000 cells/well in 24-
well plates) in complete medium. After 12 or 24 h the medium was replaced either with complete 
culture medium containing DMSO (untreated control cells) or with complete medium supplemented 
with the compounds 18 or 57 dissolved in DMSO (<1% v/v of medium). 
Cell Viability Assay. The methodology for the evaluation of the growth of human MCF-7 breast 
carcinoma, OVCAR-8, and NCI/ADR-RES cells, obtained from the National Cancer Institute drug 
screening laboratory, was previously described, except that cells were grown for 96 h for IC50 
determinations.61 
Cell viability in Hela, HT-29 and A549 cells was determined using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) colorimetric assay. The test is based on the ability of 
mitochondrial dehydrogenase to convert, in viable cells, the yellow MTT reagent into a soluble blue 
formazan dye. Cells were seeded into 96-well plates to a density of 7x103/100 μL well. After 24 h of 
growth to allow attachment of cells to the wells, compounds were added at various concentrations 
(from 0.01 to 25 M). After 48 h of growth and after removal of the culture medium, 100 μL/well of 
medium containing 1 mg/mL of MTT was added. Cell cultures were further incubated at 37 °C for 2 h 
in the dark. The solution was then gently aspirated from each well, and the formazan crystals within the 
cells were dissolved with 100 µL of  DMSO. Optical densities were read at 550 nm using a Multiskan 
Spectrum Thermo Electron Corporation reader. Results were expressed as a percentage relative to 
vehicle-treated control (0.5% DMSO was added to untreated cells), and the IC50 values were 
determined by linear and polynomial regression. Experiments were performed in triplicate. 
231-MDA and A549 cells were plated at different cellular densities in order to test the compounds 
on logarithmic phase cells. Test compounds were added after cell adhesion. On the day of the assay, 10 
μL MTT (5 mg/mL) was added to each well, and cells were incubated for 2 h (37 °C, 5% CO2). When 
dark crystals appeared at the well bottom, culture medium was discarded, and ethanol (100 μL) was 
added to each well to solubilize the crystals, yielding a purple solution. Absorbance was read with an 
enzyme-linked immunosorbent assay (ELISA) reader at 570 nm. 
The antiproliferative effect of the tubulin polymerization inhibitors on cell proliferation was 
evaluated against HCT 116, HCT 15, Messa and Messa/Dx5 tumor cell lines using the CellTiter-Glo 
luminescent cell viability assay (Promega, Madison, WI) according to the manufacturer’s instructions. 
The cells, in exponential growth, were incubated for 72 h at different concentrations of the inhibitors. 
Then an equivalent of the CellTiter-Glo reagent was added, the solution was mixed for 2 min in order 
to induce cell lysis, and the luminescence was recorded after a further 10 min. GI50 values were 
calculated using the parameters of a non-linear regression analysis program (GraphPad PRISM™ 
statistics software). 
The effects of the treatments with compounds 18 or 57 on U87MG cell survival/growth were 
estimated by a colorimetric MTS conversion assay32 and Trypan blue exclusion assay.59 The MTS 
assay was used to determine IC50 values on U87MG cell survival following 24 h of treatment. U87MG 
cells were seeded in 96-well plates and incubated with compound concentrations ranging from 0.1 nM 
to 20 M (DMSO as control). After 24 h, MTS reagent was added, and the absorbance at 590 nm was 
measured by a microplate reader (Wallac, Victor 2, 1420 Multilabel Counter, PerkinElmer). The 
percentage of proliferating cells after compound exposure was calculated with respect to control cells 
(100%). Sigmoid-dose response curves were performed using Graph-Pad Prism 4 software (Graph-Pad 
Software Inc, San Diego, CA). 
The Trypan blue exclusion assay was used to examine the effects of compound treatments on 
U87MG cell survival. U87MG cells were seeded in 24-well plates and exposed to 1 nM to 10 M 
compound concentrations for 8, 24 and 48 h. After exposure, the number of viable (white) and dead 
(blue) cells were counted using a microscope, and the percentage of viable or dead cells was calculated 
with respect to control cells (100%). 
Immunofluorescence (IF) and microscopy. HeLa epithelial cells were grown in Dulbecco’s 
Modified Eagle medium (D-MEM) supplemented with 10% FBS at 37 °C with 5% CO2. All 
compounds were dissolved in DMSO (0.1% final concentration) and used at the indicated 
concentrations for 24 h.  
HeLa cells were seeded at 3x105 cells in culture dishes containing sterile coverslips coated with 
poly-L-lysine. At the end of the treatment, they were directly fixed in methanol for 10 min at –20 °C 
and processed for IF with either mouse anti-alpha-tubulin antibody (Sigma clone B5.1.2, 1:2000 
dilution) followed by FITC-conjugated goat anti-mouse secondary antibody (Jackson Immunoresearch 
Laboratories, 115-095-068; 1:200) or with mouse anti-cyclin B1 antibody (Santa Cruz, GNS1, 1:50) 
followed by Texas Red-conjugated horse anti-mouse (Vector, TI-2000, 1:800) secondary antibody. 
Slides were counterstained with 0.05 µg/mL DAPI (Sigma) and mounted in Vectashield (Vector). Cells 
were analyzed under an epifluorescence Olympus AX70 microscope with a CCD camera (Diagnostic 
Instrument, Spot RT slider model 2.3.0). Unfixed cell cultures were observed under an inverted 
NIKON TE 300 microscope with a 10x objective and images were acquired using the ACT-1 software 
and a DMX1200 CCD (resolution 1280x1024 pixels). 
Flow cytometric analysis. Cell cycle distribution was analyzed after incubation with PI (Sigma-
Aldrich), whereas apoptosis was analyzed with Annexin V-FITC (Immunological sciences, IK-11120) 
staining alone, or with Annexin V-FITC in combination with PI. Cell samples were analyzed in a 
Coulter Epics XL cytofluorometer (Beckman Coulter) equipped with EXPO 32 ADC software. Data 
from at least 10 000 cells per sample were acquired. 
Evaluation of mitochondrial potential. JC-1 (Invitrogen, T3168, Carlsbad, CA) is a cationic dye 
that exhibits potential-dependent accumulation in mitochondria indicated by a fluorescence emission 
shift from green (~525 nm) to red (~590 nm). Consequently, mitochondrial depolarization is indicated 
by a decrease in the red/green fluorescence intensity ratio and can be quantified by using fluorescence 
microscopy.33b To evaluate the mitochondrial depolarization induced by drug treatment, U87MG cells 
were seeded in 96-well plates and stained for 10 min in medium containing JC-1 at a final 
concentration of 50 μg/mL. After removal of JC-1, fresh medium containing the drug at 100 nM 
(approximately its IC50 value in U87MG cells) or 30 M CCCP, a standard mitochondrial potential 
dissipation drug, was added to the cells. Immediately and 24 h after the treatment, pictures were taken 
under an Axiovert fluorescent microscope (Zeiss) using the filter set 10, 488010-0000 (Zeiss) 
(excitation 450–490: emission 515–565). Pictures were then split in the RGB channels (red and green) 
and analysed by using the program ImageJ.62 For each treatment, the red/green fluorescence ratio 
obtained at 24 h was normalized with respect to red/green fluorescence ratio obtained at 0 h. 
ROS production. The generation of ROS was assessed by the fluorogenic probe DCFH2-DA 
(Molecular Probes, Invitrogen) in U87MG cells after compound exposure (DMSO, H2O2 as control 
standard). DCFH2-DA is a reduced and acetylated form of fluorescein used as an indicator for ROS in 
cells.63 This nonfluorescent molecule is readily converted to a green-fluorescent form (FDA) when the 
acetate group is removed by intracellular esterases and an oxidation by ROS occurs within the cell. 
U87MG cells were seeded in 96-wells plate, washed in PBS/10 mM glucose and loaded with 10 M 
DCFH2-DA for 30 min in the dark at 37° C. Afterwards, the cells were washed with the same medium 
and incubated with or without the compound at 100 nM. Fluorescence increase was estimated in a plate 
reader at 485 nm (excitation) and 520 nm (emission) after 1, 5, 15 and 60 min (Wallac, Victor 2, 1420 
Multilabel Counter, PerkinElmer). The fluorescence values were normalized between samples for cell 
number content and assessed by a crystal violet cell staining assay. Crystal violet is an intense stain that 
binds to cell nuclei and gives an A595 reading that is proportional to cell number. After washing with 
PBS/10 mM glucose, the cells were incubated with crystal violet for 30 min at room temperature. After 
washing, a solution of 1% SDS was added to each well, and the plates were shaken mechanically for 1 
h at room temperature. A595 was then determined on a plate reader. The measured optical density 
readings indicated the relative number of cells in each well, and this was used to normalize the 
absorbance obtained with FDA. 
Statistical analyses. For data analysis and graphic presentations, the nonlinear multipurpose curve-
fitting program Graph-Pad Prism (GraphPad) was used. All data are presented as mean ± SEM. 
Statistical analysis was performed by one-way analysis of variance (ANOVA) with Bonferroni’s 
corrected t-test for post-hoc pair-wise comparisons. P < 0.05 was considered statistically significant. 
In vivo vascular disrupting effects. This study was approved by the institutional ethical committee 
for the use and care of laboratory animals. Six adult WAG/Rij rats (Iffa Credo, Brussels, Belgium) 
weighing 250 g received intrahepatic implantation of bifocal rhabdomyosarcoma allografts, which 
mimics hypervascular human liver metastases as previously described.34 Three rats bearing 6 liver 
tumors in total were thus prepared for studying 18 and 57 separately. The growth of tumors was 
monitored with MRI until their diameter reached about 10 mm for therapy. MRI was carried out with a 
clinical 3.0T whole-body MR magnet (Trio; Siemens, Erlangen, Germany) with a maximum gradient 
capability of 45 mT/m by using an 8-channel phased-array wrist coil (In vivo, Latham, NY). The rat 
was gas-anesthetized with 2% isoflurane in the mixture of 20% oxygen and 80% room air, through a 
mask connected by a tube to a Harvard Apparatus system (Holliston, MA), and placed supine in a 
plastic holder. The penile vein of the rat was cannulated for MRI contrast agent or VDA compound 
administration. With intravenous bolus of gadoterate meglumine (Dotarem®; Guerbet, Brussels, 
Belgium) at 0.1 mmol/kg, contrast enhanced T1 weighted MRI (CE-T1WI)35 was performed at 
baseline, 1 h and 24 h post-VDA treatment to document intratumoral vascular disrupting event. After 
baseline CE-T1WI, a VDA solution of  18 or 57 was intravenously injected at a dose of 15 mg/kg for 
subsequent evaluation of the therapeutic effects.  
LC-MS/MS Analytical method. Samples from the metabolic stability, solubility and permeability 
assays were analyzed under the following conditions: UPLC (Waters) interfaced with a Premiere XE 
Triple Quadrupole (Waters). Eluents were: phase A: 95% H2O, 5% acetonitrile + 0.1% HCOOH; phase 
B: 5% H2O, 95% acetonitrile + 0.1% HCOOH. Flow rate 0.6 mL/min; column, Acquity BEH C18, 50 x 
2.1 mm, 1.7 µm at 50 °C; injection volume, 5 µL: LC–MS/MS analyses were carried out using an 
ESI(+) interface in multiple reaction monitoring mode. 
Metabolic Stability. Compounds 18, 20, 55 and 57 were dissolved in DMSO in duplicate at a final 
concentration of 1 µM and preincubated for 10 min at 37 °C in potassium phosphate buffer pH 7.4, 3 
mM MgCl2, with rat liver microsomes (Xenotech) at a final concentration of 0.5 mg/mL. After the 
preincubation period, reactions were started by adding the cofactors mixture (NADP, Glc6P, G6P-DH). 
Samples were taken at times 0 and 30 min and added to acetonitrile to stop the reaction and 
centrifuged. Supernatants were analyzed and quantified by LC-MS/MS. A control sample without 
cofactors was always added in order to check the stability of test compounds in the reaction mixtures. 
7-Ethoxycoumarin was used as a reference standard. A fixed concentration of verapamil was added in 
every sample as an internal standard for LC-MS/MS. The percent of test compound remaining after a 
30 min incubation period was calculated from the peak area relative to the area of the compound after 
the 30’ incubation time. 
Aqueous Solubility. The solubilities of compounds 18, 20, 55 and 57 were measured using  an high 
throughput screening assay format. Samples prepared at the target concentration of 200 M were 
placed in a 96-well filter plate and incubated at room temperature for 90 min. The plate was then 
filtered, and solutions were analyzed by LC/MS-UV. Final concentrations are evaluated by comparing 
the area under the curve of the MeOH stock solution with those of the test compound solutions. 
Caco-2 Cell Permeability. Caco-2 cells (ECACC) were cultured in DMEM, 10% FBS, 1% NEAA, 
Hepes buffer 10 mM and 50 U penicillin and 50 ug/mL streptomycin and split at confluence by 
trypsinization. For transport studies, 200,000 cells/well were seeded on Millicell 24-well cell culture 
plates. After 24 h at 37 °C in a humidified, 5% CO2 atmosphere, the medium was exchanged for 
Enterocyte Differentiation Medium with additives (Becton Dickinson), which allows Caco-2 cells to 
establish within three days a differentiated enterocyte monolayer. TEER, measured with a Millicell-
ERS (Millipore, Corp), must be >1000 . Transport across the Caco-2 monolayer was determined by 
adding a 10 M solution of compound in DMEM (1% final concentration of DMSO) to the side from 
which permeability was to be determined. The A→B transport across Caco-2 monolayer cells was 
determined by adding the compound to the apical side at pH 6.5. After 2 h, the basolateral side solution 
at pH 7.4 and the apical and starting solutions were analyzed by LC-MS/MS. In the B→A experiment, 
the compound was added to the basolateral side and collected on the apical side. Monolayer integrity 
was assessed with a lucifer yellow assay at the end of each experiment. The apparent permeability 
(Papp) was calculated with the following equation: 
Papp = J/Co 
where: J=flux (dX/dt  per A) and Co=donor concentration (µM) at t=0; dX/dt=change in mass (X,nmol) 
per time (t,sec), A=filter surface area (cm2). 
CYP450 Inhibition. Compounds 18, 20, 55 and 57 were evaluated in a 96-well plate containing an 
appropriate buffer and a NADPH regenerating system. Cytochrome P450 inhibition experiments were 
carried out according to the manufacturer’s instructions (BD Biosciences, Franklin Lakes, NJ, USA). 
The compounds were dissolved in a 96-well plate at a 10 µM final concentration in potassium 
phosphate buffer (pH 7.4) containing an NADPH regenerating system. For all enzyme/substrate pairs, 
the final cofactor concentrations were 1.3 mM NADP+, 3.3 mM glucose-6-phosphate, and 0.4 UmL 
glucose-6-phosphate dehydrogenase. The reaction was initiated by the addition of specific isoenzymes 
(Supersomes, Gentest) and substrates at 37 °C. Furafylline (for CYP1A2, 100 mM), sulfaphenazole 
(for CYP2C9, 10 mM), tranylcypromine (for CYP2C19, 500 µM), quinidine (for CYP2D6, 0.5 mM), 
and ketoconazole (for CYP3A4, 1.66 mM) were employed as control inhibitors in one-third serial 
dilution. Incubations were carried out for 15 min (0.5 pmol CYP1A2, 5 mM 3-cyano-7-
ethoxycoumarin), 30 min (0.5 pmol CYP2C19, 25 mM, 3-cyano-7-ethoxycoumarin; 1 pmol CYP3A4, 
50 mM 7-benzyloxy-4-(trifluoromethyl)-coumarin; 1.5 pmol CYP2D6, 1.5 mM 3-[2-(N,N-diethyl-N-
methylamino)ethyl]-7-methoxy-4-methylcoumarin), or for 45 min (1 pmol CYP2C9, 75 mM 7-
methoxy-4-(trifluoromethyl)-coumarin). The reaction was then quenched by adding 75 mL of a mixture 
containing 80% CH3CN and 20% Tris base (0.5 m), and plates were read on a fluorimeter at the 
appropriate emission/excitation wavelengths. The percentage inhibition was calculated relative to 
enzyme samples without inhibitors. 
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